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Despite advances in its treatment, the incidence of renal diseases has been consistently 
increasing. Hence, there is a need to understand the underlying molecular mechanisms of the 
progression of kidney diseases. Recent research implicates inflammation as an important 
mediator of renal injury. We hypothesized that inhibiting Toll-like receptor 4 (TLR4), an 
upstream modulator of several inflammatory pathways, would prevent the progression of renal 
diseases.  
First, we determined the mechanism by which AngiotensinII (AngII)-induced 
inflammation is modulated by TLR4 using an in vitro model of rat tubulo-epithelial cells. We 
blocked TLR4 using gene silencing strategy in NRK52E cells. In TLR4-silenced cells, the 
expression of TLR4 was decreased, activation of NF-κB was reduced, inflammation and 
oxidative stress were attenuated, suggesting a role for TLR4 in potentiating AngII-induced renal 
inflammation. 
We then focused on an in vivo acute kidney injury (AKI) model to elucidate the effect of 
TLR4 in AKI. We used lipopolysaccharide (LPS), a specific ligand of TLR4, to induce AKI. We 
injected one group of rats with VIPER, a TLR4 inhibitory peptide, before LPS administration. 
We also used blueberry as a non-pharmacological approach to study if blueberry could protect 
against LPS-induced AKI. Compared to LPS-administered rats, the BB-pretreated animals 
exhibited improved renal hemodynamics, attenuated expression of TLR4 and inflammation. The 
results in the BB-pretreated group were consistent with the VIPER-treated rats. This indicates 
that TLR4 is an important mediator in LPS-induced AKI, and suggest that BB, by inhibiting 
TLR4, is a viable non-pharmacological option to decrease AKI. 
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We also examined the effect of TLR4 signaling and its downstream mechanism in an 
animal model of metabolic syndrome-associated chronic kidney disease (CKD) and investigated 
if a blueberry-enriched diet could attenuate the progression of CKD. We showed that OZR 
exhibited lower glucose tolerance, exacerbated renal dysfunction and increased oxidative stress. 
Expression levels of TLR4 and, phosphorylation of ERK and p38MAPK were higher. This was 
accompanied by increased renal pathology. BB-fed OZR showed significant improvements in all 
of these parameters. This suggests that the TLR4-MAPK signaling pathway is a key to the renal 









CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 RENAL DISEASES 
1.1.1 Introduction 
Renal disease research has been of particular interest in the field of medicine over the 
past decade. Statistics show that the incidence of renal diseases is on the rise, and more than 20 
million (one in every 10) American adults have some level of kidney disease (1). Renal diseases 
are characterized by renal injury markers, reduced kidney function, and altered kidney structure. 
A renal disease is any abnormality in kidney size or shape or both, and is associated with a 
decline in the ability of the kidney to function normally for an extended period of time (2). Most 
renal diseases comprise one or more pathological conditions such as hypoalbuminemia, 
hyperkalemia or hypokalemia, an elevated serum creatinine and blood urea nitrogen 
concentration, deposition of excess matrix leading to tubulointerstitial fibrosis (3) and changes in 
the amount of urine produced. Specific markers of renal dysfunctions need to be identified and 
further confirmation is to be obtained through diagnostic techniques in order to attenuate the 
progression of renal diseases. Previous studies have identified urinary biomarkers for progressive 
renal diseases, with hematopoietic growth factor inducible neurokinin-1 (HGFIN) being one 
particular biomarker that is increased during pathological conditions of the kidneys (4). In 
general, if the renal function abnormality continues for more than 3 months, it is considered as 
end stage renal disease (ESRD)  
1.2 ESRD: ADVANCED STAGE (5) OF CHRONIC KIDNEY DISEASE 
ESRD is a major cause of mortality as it is the final stage of chronic renal failure. Its 
occurrence differs depending upon age, sex and race. The Kidney Disease Outcomes Quality 
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Initiative (KDOQI) has classified chronic renal failure into various stages. Stage 1 consists of 
kidney damage accompanied by a normal or increased glomerular filtration rate (GFR). A slight 
reduction in GFR from normal (> 90mL/min/1.73m
2
) i.e 60-89 mL/min/1.73m
2 
indicates 
abnormal blood and urine processing capacity of the kidneys and is considered as Stage 2. In 
Stage 3, the GFR further reduces to 30-59 mL/min/1.73m
2
. Stage 4 has a much more decreased 
GFR of 15-29 mL/min/1.73m
2
 and the severity of the disease at this stage might require a renal 
transplant. A GFR below 15 mL/min/1.73m
2 
is categorized as Stage 5 and this stage necessitates 
renal replacement therapy (5) or a continuous dialysis process.  
1.2.1 Major Causes of ESRD 
End-Stage Renal Disease is a highly progressive and irreversible condition. The causes of 
ESRD include diabetes mellitus, hypertension, chronic glomerulonephritis (6), polycystic kidney 
disease, obesity (7), oxidative stress, and abnormalities in the renin-angiotensin system. Each of 
these results in chronic damage to the kidneys via different mechanisms.  
Hypertension is a major cause of ESRD (8-11). Kidneys and the vascular system highly 
depend on each other for good health. The renal system comprises extensive vascular and 
capillary networks, which supply blood for the proper functioning of the kidneys. A prolonged 
high blood pressure condition can cause damage to the arterial and capillary systems, causing a 
reduction in the supply of blood to the kidneys. This induces nephrotic injury, which further 
affects the ability of the kidneys to properly filter blood and regulate blood pressure, thus 
contributing to the progression of ESRD (12, 13). Renal failure brings about an increase in the 
serum creatinine level. Studies have shown that individuals are 3 times more at risk for kidney 
disease if the serum creatinine level is above 1.7mg/dL (14). Renin-angiotensin system mediated 
development of ESRD can also be associated with hypertensive state in patients. Hypertension is 
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known to induce oxidative stress and inflammation, thus contributing to the progression of 
kidney diseases.  
Oxidative stress and related inflammation cause kidney damage via altering the redox-
sensitive pathways. Previous studies have reported an aberrant antioxidant mechanism in ESRD 
patients (15, 16). The alterations that occur in these antioxidant pathways mainly result in an 
increased production of reactive oxygen species but the kidneys are either unable to clear these 
excess oxidants or the antioxidant defense mechanism is impaired (7). The superoxide dismutase 
activity of the red blood cells has been reported to be reduced in ESRD (17).  
Metabolic syndrome has been yet another prominent cause of ESRD in people. Almost 
half of all ESRD patients are diabetic (18, 19). High levels of blood sugar causes damage to the 
micro and macrovasculature system within the kidneys and eventually results in proteinuria (20). 
Obesity and the dyslipidemia associated with obesity have been proven to be major factors that 
can cause chronic kidney diseases (18). A reduction in the levels of high density lipoprotein and 
serum apolipoprotein A-1 has been reported in ESRD subjects. Further, an increased low density 
lipoprotein level and hypercholesterolemia have been characterized in patients affected by ESRD 
(18). Very low density lipoprotein concentration is also found to be increased in later stages of 
ESRD and studies have suggested a possible reason for this to be the inability of the kidneys to 
adequately clear these molecules (21, 22).   
1.2.2 Effects of ESRD 
Patients with chronic renal failure develop cardiovascular problems that progress along 
with the severity of the disease. A subject in an early stage of renal failure may also be affected 
by cardiovascular diseases even though there will only be a small reduction in his/her GFR (23, 
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24). This can be understood from a deeper review of the major causes of ESRD, most of which 
are also factors that contribute to cardiovascular diseases. Oxidative stress, inflammation and 
hypertension, which are major causative agents of ESRD are said to play a pivotal role in the 
development of cardiovascular problems in these patients. Several studies have shown an 
increase in the oxidative stress specific biomarkers, such as malondialdehyde and lipid 
peroxidases, in ESRD patients (25). Furthermore, it has been demonstrated that the concentration 
of malondialdehyde is inversely proportional to the GFR (17).  
Another interesting effect of ESRD is an increased level of adiponectin in the patient’s 
plasma. Usually the adiponectin level is found to decrease in diseased conditions but in the case 
of chronic kidney diseases, adiponectin levels are found to be higher than normal (26). 
Researchers are of the opinion that this increased production of adiponectin is to compensate for 
the metabolic abnormalities that are caused due to ESRD (27). 
Proteinuria is another significant effect of chronic renal failure. Proteinuria also has a 
vicious cycle effect by which it promotes the progression of a chronic kidney disease to ESRD. 
Due to the decrease in the number of nephrons in chronic kidney disease, the load on the 
remaining functional nephrons increases in order to maintain the GFR. This excess burden on the 
nephrons causes damage of the glomeruli in these nephrons. Proteins escape the glomerular 
filtration membrane and are reabsorbed by the epithelial cells of tubules. These reabsorbed 
proteins cause the release of many proinflammatory molecules, which further enhance 
inflammation (28).  
Chronic renal disease, as it progresses, leads to a decrease in the hydroxylase activity in 
the kidneys. This brings about a decline in the serum concentration of 1, 25-dihydroxyvitamin D. 
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This results in hyperparathyroidism in patients, which is yet another major effect of ESRD (29). 
Thus ESRD has a wide spectrum of effects on the patient and it is thought that there still exist 
several causes and effects of ESRD, which are yet to be unraveled.  
1.2.3 Current Treatments for ESRD 
Since kidneys regulate fluid homeostasis, their proper functioning is critical. Any 
hindrance to the physiological role of the kidneys can affect the entire body’s health. Most major 
causes of ESRD, like hypertension or diabetes, can be prevented. Angiotensin receptor blockers 
and inhibitors of angiotensin converting enzyme are used to prevent hypertension-associated 
renal dysfunctions. Careful monitoring and control of protein intake also aids in the prevention 
of the progression of chronic renal failure (30). As ESRD is an irreversible pathological 
condition, the currently available treatments include intermittent dialysis or a renal transplant. 
Both these treatment techniques are highly expensive and have adverse consequences.  
Dialysis is a technique by which the filtration of substances, like water, excess mineral 
salts and other waste products, by the kidneys is carried out ex vivo. Dialysis is initiated only at 
Stage 4 or Stage 5 of chronic kidney disease. There are different types of dialysis – hemodialysis 
and peritoneal dialysis being the major ones. Dialysis employs an artificial kidney and a dialyzer. 
A flow of blood passes from the patient into an artificial kidney, which removes the unwanted 
substances into the dialyzing fluid via diffusion through a membrane (31).  
Renal transplant is yet another current therapy for ESRD. But these techniques have to be 
strictly monitored to control transplant rejections or adverse immune responses. Rejections, if 
chronic, are problematic and current treatments are ineffective. Acute humoral rejections are also 
common in patients (32). 
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1.3 EXPERIMENTAL MODELS OF RENAL DISEASES 
1.3.1 Hypertensive Kidney Disease 
The physiological role of kidneys in the development and progression of hypertension is 
well documented. Maintenance of salt and water homeostasis being the primary function of the 
kidneys, any change in fluid volume or salt concentration is expected to affect kidney function. 
Similarly, an elevation in arterial pressure will result in a functional abnormality in the renal 
vasculature (33, 34), thus contributing to the development of renal diseases.  
The animal models of hypertensive renal disease that are widely used include genetic 
models such as the spontaneously hypertensive rats (SHR) (35) and Dahl salt-sensitive (DS) rats 
(36). Apart from these genetic models, an angiotensin II treated animal model of hypertension is 
also used in order to study hypertension-associated kidney disorders (37). The renin-angiotensin 
system is a major factor in hypertensive renal dysfunction and studies have demonstrated that 
injecting angiotensin peptide or renin induced hypertension in rats (37). Further it has also been 
shown that treatment with antagonists or blockers of angiotensin was able to prevent the rise in 
blood pressure and protect against renal injury in hypertensive rats (37).   
1.3.2 Sepsis-induced Acute Kidney Injury (AKI) 
AKI is one of the most prevalent forms of kidney diseases that is reported to predispose a 
person to more complicated kidney disorders such as CKD (38). Sepsis is the most common 
cause of AKI (39, 40). Sepsis is a multiple organ dysfunction that occurs when an invasive 
pathogen enters a host. Previous studies proposed that the hemodynamic imbalance and 
hypotension induced by sepsis results in under-perfusion of the kidneys and this leads to kidney 
injury (41).  
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Lipopolysaccharide (LPS) is a component of the gram-negative bacterial cell wall that is 
used to mimic sepsis in experimental animal models, especially in rodents. LPS injection has 
been shown to decrease renal blood flow and glomerular filtration rate (42), even without a 
change in blood pressure (41). LPS also induces the production of proinflammatory cytokines 
such as TNFα (43), which can further exacerbate the renal injury. 
1.3.3 Metabolic Syndrome (MetS) Associated Kidney Disease 
MetS was first described in the year 1988 as a combination of selected risk factors that 
predisposes an individual to cardiovascular and renal diseases (44, 45). The risk factors that 
comprise the MetS include obesity, hypertension, insulin resistance, dyslipidemia and 
hyperglycemia (46).   
The genetically obese Zucker rat (OZR) is one of the best rodent models of MetS as it 
expresses all the risk factors involved in MetS. It is also known to closely share the 
characteristics of obesity in humans (47). These OZR have a mutated leptin receptor and hence 
are hyperphagic (48). Previous studies have shown an age-dependent reduction in renal function 
in the OZR compared to their lean controls (LZR). Pamidimukkala J et al and Slyvka Y et al 
have shown that OZR exhibited reduced renal function parameters, namely GFR and RBF even 
at 12-14 weeks of age (49, 50).  
1.4 OXIDATIVE STRESS IN RENAL DISEASES 
A physiological decline in renal function with age has been reported in adults starting 
from age 30 although this reduction in the efficiency of kidney cannot yet be termed CKD (51). 
CKD is identified in those who have other risk factors associated with an increased oxidative 
stress and inflammation (51). Oxidative stress is an imbalance between the rate of production of 
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free radicals and their degradation by antioxidant enzyme systems that results in an unwarranted 
accumulation of the radicals (52). The majority of the reactive oxygen species (ROS) generation 
takes place in the mitochondria during the electron transport chain when some electrons leak 
from the proper chain and reduce the oxygen molecules to form superoxide radicals (53). The 
release of these ROS triggers further ROS production via radical chain reactions. During normal 
physiological conditions, ROS such as hydrogen peroxide, hydroxyl radical, and hypochlorite 
ion are available at low concentrations where these free radicals play vital roles of being 
regulators of intracellular signaling mechanisms, nitric oxide synthesis, immune responses and 
apoptosis (52). At high concentrations, ROS alter various biomolecular functions, and induce 
pathological processes and result in cellular damage (52, 54). Furthermore, ROS contributes to 
the synthesis of cytotoxic reactive nitrogen species (RNS) such as peroxynitrite, which can 
modulate cell signaling and has vasoconstrictive properties (55). Although the short half-life of 
free radicals makes their detection difficult, there are strong markers of oxidative stress 
associated with various diseases that have a longer half-life. These markers of oxidative stress 
that are potential contributors of renal disease pathogenesis include LDL, reactive carbonyl 
compounds, advanced glycation end-products (AGE) and thiol compounds (52, 56, 57).  
Several research and clinical studies have implicated oxidative stress in renal dysfunction 
(58-60). High malondialdehyde (MDA) levels are considered as an important indicator of 
cardiorenal abnormalities (61) and accumulation of AGE is associated with chronic renal failure 
(58). The accumulation of these compounds ensues as a result of the inefficiency of the kidneys 
to clear them in a timely manner. Kao et al (62) and Droge et al (61) have reported that oxidative 
stress appears even in the early stages of renal decline. Different mechanisms have been reported 
for an increased oxidative stress in renal diseases. The prognosis of renal diseases is usually 
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associated with hypertension, diabetes, low antioxidant enzymatic levels and the inability to clear 
ROS, all of which can result in an increased oxidative stress in these patients. Further, CKD is a 
chronic low grade inflammatory disease (63) and this chronic inflammation can itself lead to an 
increased oxidative stress and contribute to the progression of renal diseases. One of the 
important inflammatory molecules that has been of particular interest in renal disease recently is 
the Toll-like receptor 4, which is upstream to several inflammatory cascades.   
1.5 TOLL-LIKE RECEPTOR 4 (TLR4) IN RENAL DISEASES 
The TLR family of proteins was first identified as “Toll” in Drosophila where it was 
found to play an important role in the innate immune system of the organism (64). Subsequently 
it was discovered that these TLR proteins were evolutionarily conserved and mammalian TLRs 
were found to be homologous to the TLR in drosophila. TLRs are transmembrane receptors 
belonging to the IL-1R receptor superfamily (65). Eleven TLR proteins are characterized in 
humans to date (65). Among these, TLR4 is one of the most studied TLR proteins.  
1.5.1 TLR4 and its ligands 
TLR4 is critical for the signaling of a variety of ligands. TLR4 is known to be an 
important component of LPS-induced endotoxic shock (66). The binding of LPS to TLR4 on the 
cell membrane initiates a sequence of inflammatory reactions resulting in the release of 
proinflammatory cytokines from immune and non-immune cells. Research studies carried out by 
different groups have established the importance of TLR4 in LPS signaling. Previous studies 
found an impaired responsiveness to LPS in mice that had a mutated TLR4 gene (67, 68). TLR4-
mutated human patients also showed a hypo-responsiveness to LPS (69). Medvedev et al., 
showed that phosphorylation of specific tyrosine residues in TLR4 is essential for LPS-induced 
endotoxin signaling (68).  
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In addition to LPS, TLR4 can bind a variety of other ligands.  The heat shock proteins, 
Hsp60 (70) and Hsp70 (71) have been shown to bind with TLR4 and activate mitogen-activated 
protein kinases (MAPK) and NFκB signaling. Recently, it has been found that TLR4 also acts as 
a receptor for pathogen associated molecular patterns (PAMP) and danger associated molecular 
patterns (DAMP), which are mostly endogenous (72-74). An endogenous DAMP that acts as a 
ligand for TLR4 and initiates an immune response in non-infectious inflammation is HMGB1 
(75). 
1.5.2 TLR4 signaling in renal diseases 
The basic mechanism of ligand binding with TLR4 in infectious and non-infectious 
cellular injury may be associated with the progression of renal diseases. Emerging evidence 
indicates that TLR4 plays a crucial role in the pathogenesis of several kidney diseases. However, 
the exact molecular mechanism by which TLR4 mediates this effect has not been completely 
elucidated to date. LPS-exposed, murine, renal tubular epithelial cells have an upregulated TLR4 
expression, which suggests that TLR4 expression in these cells is associated with sepsis-induced 
tubular injury (76). Cunningham et al., demonstrated that TLR4-deficient mice were resistant to 
inflammatory acute renal injury induced by LPS (77). Infectious diseases of the kidney are also 
predicted to be associated with TLR4 signaling, wherein the renal cells recognize the invading 
pathogens, activate the macrophages and dendritic cells, and elicit an inflammatory response (78, 
79).  Even though the major causes of AKI are understood to be either ischemic or nephrotoxic 
injury, most clinical cases are associated with multiple causes, including sepsis. It is interesting 
to note that sepsis triggers an activation of TLR4 that can specifically induce downstream NFκB 
signaling (76, 80). Therefore, TLR4 could be a possible key to the renal injury and the 
progression of AKI.   
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Glomerulonephritis is another renal disorder that has been associated with TLR4. Anti-
myeloperoxidase (anti-MPO) is an inducer of glomerulonephritis. It has been found that an 
increased TLR4 expression was observed in the glomerular cells of mice treated with anti-MPO 
(81, 82). This injury was concomitant with an increased neutrophil recruitment in the kidneys of 
these mice. TLR4-deficient mice had an attenuated glomerulonephritis (81).  Kidney biopsies 
from human CKD patients also revealed an increased expression of TLR4, which correlated with 
increased expression of MCP-1 and TGF-β, which are markers of inflammation and fibrosis 
respectively (83). Recent studies conducted in animal models of diabetic nephropathy show that 
TLR4 activation is associated with renal podocyte injury and fibrosis in these animals. Again, 
TLR4 knockout mice exhibited resistance to the development of diabetic nephropathy, which 
was associated with attenuated inflammation and cellular injury (84). All of these previous 
findings clearly indicate a vital role for TLR4 in the development of renal diseases but the exact 
mechanism of its action is not yet completely understood.  
1.6 HIGH MOBILITY GROUP BOX 1 (HMGB1) PROTEIN IN RENAL DISEASES 
High mobility group box 1 (HMGB1) is an evolutionarily conserved non-histone nuclear 
binding protein and an endogenous ligand for TLR4 and receptor for advanced glycation end-
products (RAGE) (85-87). In cells, HMGB1 is known to have the ability to shuttle between the 
nucleus and cytoplasm, although in normal conditions its presence is restricted to the nuclei to 
bind chromatin (88). During tissue injury, HMGB1 is released by activated immune cells and/or 
injured cells into the extracellular milieu. Extracellular HMGB1 functions as a danger-associated 
molecular pattern (DAMP) which can induce robust activation of the innate immune system (89) 
and also acts as a major proinflammatory mediator of inflammatory diseases (86). HMGB1 has 
been reported to contribute to the progression of several chronic inflammatory diseases including 
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atherosclerosis (90). Research evidence suggests that HMGB1 plays an important role in renal 
diseases, such as acute kidney injury (91, 92), glomerulonephritis (93), diabetic nephropathy 
(94), lupus nephritis (95) and renal allograft rejection (96). 
1.6.1 Structure of HMGB1 
HMGB1 is the most highly expressed high mobility group protein, with about a million 
molecules present in a single cell (97). HMGB1 is a 215 residue protein organized into two 
separate DNA binding domains, namely the N-terminal A-box and the B-box. In addition to 
these DNA-binding domains, the structure of HMGB1 also contains an acidic tail at the C-
terminal end. The A-box and the B-box each are formed of approximately 75-80 residues and the 
C-tail has about 30 amino acids (96). The B-box comprises the binding sites for TLR4 (residues 
89-108), the major ligand of HMGB1 that is responsible for its proinflammatory and cytokine 
activity (98, 99) whereas the A-box acts as an antagonist of the endogenous HMGB1 protein 
(99), thereby serving to inhibit the proinflammatory effects of cytoplasmic HMGB1 (100).  
1.6.2 HMGB1 release and signaling 
Intranuclear HMGB1 is a DNA binding protein that regulates a number of DNA-
associated activities including nucleosome stability, nucleosome release, gene transcription, 
genome chromatinization, DNA replication and DNA repair (97). In addition to these 
intracellular roles, HMGB1 has been identified to play a vital role as an extracellular mediator of 
inflammation (92, 96). The translocation of HMGB1 from the nucleus to the extracellular 
environment is described to occur in two different ways. Activated immune cells such as 
macrophages, monocytes and dendritic cells secrete HMGB1 (active pathway) in response to 
inflammation (101, 102) and damaged or dying cells release HMGB1 in a passive manner (96). 
Immune cells upon activation by LPS undergo acetylation of lysine residues, which is a signal 
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for HMGB1 translocation (102). Although the exact mechanism of HMGB1 release is yet to be 
elucidated, research findings suggest that the inflammasomes, an innate immune system 
component, play a major role in this process. Lamkanfi et al showed that HMGB1 release from 
LPS-exposed macrophages required the activation of NLRP3 inflammasome (103).  
A growing body of evidence indicates that HMGB1 can bind to multiple receptors, such 
as TLR2 (104), TLR4 (87, 105, 106) and RAGE (106), in the kidneys during inflammatory 
injury. Different release mechanisms induce the release of different redox forms of HMGB1. 
Necrotic cells trigger the release of a fully-reduced isoform of HMGB1, which then forms a 
heterodimer with the CXCL12 chemokine to signal through CXCR4 receptor. Apoptotic cells 
release an oxidized HMGB1. The oxidized isoform of HMGB1 is not known to induce cytokine 
production or chemotaxis. Activation of the TLR4 ligand induces the release of disulfide 
HMGB1 that has thiol groups on C106 and a disulfide bond between C23 and C45 (102). 
HMGB1-TLR4 interaction has been demonstrated to signal via the MyD88-dependent pathway 
(87, 102). The binding of HMGB1 to these receptors result in the activation of NFκB signaling 
and subsequent inflammatory cascade by promoting the upregulation of proinflammatory 
cytokines (96).  
The ability of HMGB1 to activate the production of cytokines and chemokines has led to 
investigation of its role in renal diseases. HMGB1 has been implicated in a variety of kidney 
diseases, including glomerulonephritis, wherein HMGB1 levels were found to be elevated in the 
urine and serum of patients. HMGB1 also induced the activation of monocyte chemoattractant 
protein-1 (MCP-1) in these patients resulting in further translocation of HMGB1 from the 
nucleus to cytoplasm (107). Wang et al., demonstrated that HMGB1 acts as a mediator of septic 
inflammation (101), which underlines the role played by HMGB1 in AKI as it is associated with 
14 
 
sepsis-related complications. Injured renal cells in renal ischemia-reperfusion (IR) have been 
shown to release HMGB1, which binds to TLR4 receptor in leukocytes to induce the production 
of inflammatory cytokines (108). Further, a time-dependent increase in HMGB1 levels were 
demonstrated in the kidneys of rats after an IR injury (109). HMGB1 has been studied in diabetic 
nephropathy and the results show an increase in the expression of HMGB1 in diabetic rat 
kidneys (110). This also suggests HMGB1 as a possible mediator of diabetic renal injury. In 
CKD patients, HMGB1 levels were reported to correlate with GFR and the extent of 
inflammation (111). Further extensive studies are required to elucidate the exact mechanism of 
the role played by HMGB1 in kidney diseases. 
1.7 STATEMENT OF THE PROBLEM AND SPECIFIC AIMS 
A chronic inflammatory condition and oxidative stress environment induce a vicious 
cycle that can contribute renal injury and result in its progression to end stage renal disease. As a 
major inflammatory molecule that is upstream of several important inflammatory cascades, 
TLR4 activation has been implicated in the injurious effects of inflammation on the renal 
structure and function. Although previous studies have proposed a vital role for TLR4 in acute 
and chronic renal diseases, the exact signaling mechanisms by which TLR4 exerts its 
inflammatory effect in the kidneys are still poorly understood.  
The overall objective of this dissertation was to elucidate the exact signaling mechanisms 
by which TLR4 contributes to the development of different models of acute and chronic kidney 
diseases. We hypothesized that pharmacological and non-pharmacological approaches, which 
can inhibit the expression of TLR4, would prevent or delay the progression of renal diseases in 
different models of acute and chronic kidney diseases. We performed a series of in vitro and in 





Figure 1.1: The proposed signaling mechanism of the inflammatory activity of TLR4 on the 
kidney. 
Objective 1: Determine how HMGB1-TLR4 signaling mediates the angiotensin II-induced 
hypertensive renal injury in an in vitro model of rat tubular epithelial cells.   
Objective 2: Examine the role of TLR4 in a lipopolysaccharide-induced acute kidney injury 
(AKI) model and determine the beneficial effects of a blueberry supplementation in this animal 
model. 
Objective 3: Investigate the effects of a blueberry-enriched diet in improving renal function and 
reducing oxidative stress by modulating TLR4 expression in an animal model of metabolic 
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CHAPTER 2  
ANGIOTENSIN II-INDUCED HYPERTENSIVE RENAL INJURY IS MEDIATED 
THROUGH HMGB1-TLR4 SIGNALING IN RAT TUBULO-EPITHELIAL CELLS 
 
2.1 INTRODUCTION 
 Hypertension is one of the most critical predisposing factor for the development of end-
stage renal disease (ESRD). According to the American Heart Association, about one-third of the 
adult population has high blood pressure (1). While effective control of hypertension has been 
implemented by medications such as angiotensin-converting enzyme inhibitors and angiotensin-
receptor blockers, the clinical course of the disease remains progressive and its prevalence is on 
the rise (2). Consequently, new and innovative approaches for treating hypertension are needed.   
Inflammation is an important risk factor for end-organ damage (3-6) and has been implicated in 
hypertension (7, 8). A growing body of evidence suggests that inflammatory cytokines play 
important roles in the pathophysiology of renal disease (5, 9). Several groups have implicated the 
role of circulating cytokines in ESRD (10-12). These proinflammatory cytokines (PIC) cause an 
over-activation of the renin-angiotensin system (RAS), which also plays a major role in the 
pathogenesis of ESRD (13).  
 Our previous reports have shown that blocking inflammatory molecules and their 
transcription factor, nuclear transcription factor kappa B (NFkB), attenuates sympathetic activity 
(14, 15) and hypertension (8).  However, it remains unknown how inflammation is activated 
during the development of hypertension. We proposed that the interaction between the 
inflammatory cytokine protein high-mobility group box 1 (HMGB1) and toll-like receptor 4, 




 HMGB1 is a potent innate danger/damage associated signaling molecule, which is 
actively secreted by immune cells and necrotic cells (16). The release of HMGB1 marks the 
initiation of host defense or inflammatory tissue repair mechanisms (17). Receptor blocking 
studies have shown that HMGB1 is a strong endogenous ligand of TLR4 receptor (18-21). 
TLR4, a receptor found on the cell surface, mediates the proinflammatory effects (22) of its 
ligands through the NFkB signaling pathway. HMGB1 has been shown to be a pivotal factor in 
the pathogenesis of inflammatory diseases such as autoimmune disease (23), endotoxin-induced 
sepsis (24) and ischemia/reperfusion injury (25).  
 The objective of this study was to understand the molecular mechanisms contributing to 
Angiotensin II (AngII)-mediated kidney injury. In this in vitro study, we show that HMGB1 and 
its receptor TLR4 are activated in response to AngII insult in the NRK52E rat tubular epithelial 
cell line. Gene silencing of TLR4 and inhibition of HMGB1 attenuates the AngII-mediated, 
inflammatory injury in these cells. Our data provide strong evidence for the involvement of 
HMGB1-TLR4 signaling in the development of hypertensive renal injury.  
2.2 MATERIALS AND METHODS 
Renal tubular epithelial cell culture – NRK52E cell line 
 Cell lines were grown in Dulbecco’s modified eagle’s medium (DMEM) containing 10% 
fetal bovine serum (FBS) and 100 IU/ml penicillin, at 37
0
C in a humidified atmosphere of 95% 
air and 5% CO2. Unless otherwise stated, cells were plated at a density of 4 x 10
6
 cells per 60mm 
dish or 1 x 10
7 
cells per 100mm plate. All experiments were performed at 70-80% confluency. 
All treatments were done in serum-free medium. To study the effect of AngII on inflammatory 
cytokines, NRK52E cells were exposed to AngII or vehicle (control). We performed a pilot 
experiment to validate the best time-point for AngII stimulation of NRK52E cells, using a 
28 
 
previously reported (26, 27) concentration (1µM) of AngII in culture medium over a stipulated 
time course (0-24 h). At defined time-points, cells were harvested for real-time PCR for mRNA 
analysis of TLR4, HMGB1 and proinflammatory cytokines, such as TNFα and IL-1β. We 
observed that 6h was the earliest time-point at which an AngII-exerted effect was evident at the 
mRNA level. AngII treatment for 24h did not cause any significant changes in the expression of 
these genes when compared with 6h. In all subsequent experiments, cells were exposed to 1µM 
AngII for 6h. All results are presented as mean±SD or mean±SEM, and represent set of three 
independent experiments in NRK52E cells. In each experiment, n=6 per treatment groups were 
used unless otherwise stated. 
Treatment of cells with Losartan 
 In another set of experiments, cells were pre-treated with Losartan (100µM) for 2h before 
AngII exposure for 6h. The treatment dose for losartan was obtained from previous studies 
conducted on the same cell line (27). Following exposure to AngII receptor blocker, cells were 
harvested for real-time PCR, and western blot analysis.  
TLR4 siRNA construction and transfection 
 We explored the effects of TLR4 silencing by using a gene knock-down approach, RNA 
interference through the delivery of small interfering RNA (siRNA) against TLR4 (Santa Cruz 
Biotechnology, CA, USA). A scrambled sequence of the same length was used as a control. All 
treatments were done by following the manufacturer’s recommended protocols. Twenty four 
hours after plating, NRK52E cells were transfected separately in 6-well plates with TLR4siRNA 






 All treatments were performed following the manufacturer’s recommended protocol. 
HMGB1 neutralization was achieved by pretreating the cells for 4 hours using chicken anti-
HMGB1 neutralizing polyclonal antibody (IBL International Corp, ON, Canada) at a dosage of 
1µg/ml (28).   
RNA extraction and Real-Time PCR 
Semi-quantitative real-time PCR was used to determine the mRNA levels of TLR4, 
HMGB1, TNFα and IL-1β in NRK52E cells. Total RNA isolation, cDNA synthesis and RT-PCR 
were performed as previously described (29, 30). Semi-log amplification curves were evaluated 
by the comparative quantification method (2
-ΔΔct
), and GAPDH or 18s RNA was used for 
normalization of all reported gene levels. The data presented are the fold changes of the gene of 
interest relative to that of the control group. 
Western blot analysis 
For whole cell extracts, cells were washed twice with ice-cold PBS and scraped into 
100µl per dish of cell lysis buffer (Cell Signaling Technology Inc, Danvers, MA, USA), 
containing protease and phosphatase inhibitors. Samples were incubated on ice for 10 min and 
then centrifuged (12000 rpm, 5 mins, 4
º
C). The supernatants were retained. Protein 
concentrations were determined by bicinchoninic acid (BCA) method, lysates were stored at -
80
O
C until used for western blotting. 
 Cell lysates were mixed with Laemmli sample buffer (Bio-Rad Laboratories, CA, USA) 
and placed in a boiling water bath for 5 min. Proteins (30µg) were separated by SDS-PAGE 
using 10-15% resolving gels and 6% stacking gels, and then transferred onto a PVDF membrane. 
Non-specific binding sites were blocked with 5% (w/v) BSA in Tris buffered saline with tween-
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20 (TBST). Blots were probed overnight with primary antibodies. Specific primary antibodies 
included anti-HMGB1 (1:1000), anti-TLR4 (1:1000) and anti-TNFα (1:1000, Santa Cruz 
Biotechnology Inc., Texas, USA). Blots were washed with TBST, incubated with HRP-
conjugated secondary antibodies (1:10000) for 1 hour. Bands were visualized using enhanced 
chemiluminescence (ECL Plus, Amersham, NJ, USA). Band intensities were quantified using 
ImageJ software.    
Flow Cytometry 
 The cultured cells were trypsinized using 0.25% trypsin-EDTA and collected. DMEM 
was added to arrest the enzymatic action of trypsin and the cells were spun at 2000rpm for 5 
mins. The pellets of cells were re-suspended in 1X PBS. To study TLR4 expression, 1×10
6
 cells 
were incubated with anti-TLR4 (1:250) antibody for 30 minutes at room temperature. The 
samples were washed using 1X PBS to remove any unbound antibody and then incubated with 
Alexa Fluor 488 goat anti-rabbit IgG antibody (1:250) in 10% normal goat serum-PBS for 30 
minutes at room temperature. Samples were again washed. Autoflourescence and secondary 
antibody controls were also prepared.  
 Samples were analyzed on a FACScan flow cytometer (BD Biosciences, San Jose, CA) 
utilizing a 15 mW 488 nm argon-ion laser and configured for Alexa Fluor 488 fluorescence 
measurements using log amplification.  Data from total of 10,000 cells per sample were acquired 
on a Macintosh G5 workstation (Apple Computer, Cupertino, CA) running Cellquest Pro 
software (BD Biosciences, San Jose, CA).  Cellular artifact was eliminated by gating on intact 
cells based on dot plots of forward scatter versus side scatter.  Fluorescence analyses in the form 
of histograms were generated using Cellquest Pro software (BD Biosciences, San Jose, CA).  
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Percentages of cells expressing TLR4 were determined for each sample based on comparisons 
with negative controls. 
Electron paramagnetic resonance spectroscopy (EPR) 
 Total ROS and superoxide production rates were measured in NRK52E cells via EPR 
spectroscopy as previously described (29-33). The term ‘total ROS’ represents all ROS; 
however, the major  ROS detected by this method were superoxide, hydrogen peroxide, and 
hydroxyl radical, with other species as minimal contributors. Briefly, cells were incubated at 
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C with 6.6µl of CMH (200µm) for total ROS measurement; 1.5µl of PEG-SOD (50U/µl) for 
30 minutes, then CMH for an additional 30 minutes for superoxide measurement. Aliquots of 
incubated probe media were taken in 50µl disposable glass capillary tubes (Noxygen Science 
Transfer and Diagnostics, Elzach, Germany) for determination of total ROS or superoxide 
production, using previously established EPR settings (29, 32) 
HMGB1 ELISA 
 The cell culture medium was collected in sterile tubes, spun at 2000 RPM for 10 minutes. 
The supernatant was collected and stored at -80ºC. HMGB1 concentrations in the medium was 
measured using the rat high mobility group protein B1 (HMGB1) ELISA kit (MyBioSource Inc., 
San Diego, CA) using the manufacturer’s recommended protocol. 
Quantification of NFκB p65 activity 
 The NFκB p65 activity ELISA (Active Motif, USA) kit was used to assess the binding 
activity of free NFκB p65 in nuclear extracts, as described previously (29). A sandwich ELISA 






 Statistical analysis was performed either using paired t-test or one-way ANOVA with 
Bonferroni post hoc test using Prism software (GraphPad Software, CA, USA). Data are 
presented as the fold change of each gene of interest relative to controls. Results were considered 
significant when p<0.05. 
2.3 RESULTS 
AngII causes inflammatory activation of HMGB1 and TLR4 in NRK52E cells  
 To investigate the influence of AngII on HMGB1and TLR4 in renal tubular epithelial 
cells, we treated NRK52E cells with AngII (1µM) for stipulated time-points and examined the 
mRNA levels of HMGB1 and TLR4 in whole cell extracts. We also determined the gene 
expression levels of proinflammatory cytokines TNFα and IL-1β. We observed that AngII 
treated cells exhibited significant increases in HMGB1, TLR4 and the PIC after 6h of exposure 
(Figure 2.1). 
AngII exposure (6h) resulted in a seven-fold increase in TLR4 and HMGB1 mRNA 
expression, a ten-fold increase in TNFα mRNA expression and a six-fold increase in IL-1β 
mRNA expression. There was no significant change in the expression of these transcripts after 








Figure 2.1: Effect of AngII treatment on TLR4, HMGB1 and PIC expression levels in NRK52E 
cells. Serum starved rat tubulo-epithelial cells were treated with AngII on a time-dependent basis 
and mRNA expression of TLR4, HMGB1, and the proinflammatory cytokines TNFα and IL-1β 
were determined. The results are mean ± SEM of three independent experiments (n=12 per 




Treatment with losartan decreased the expression of TLR4, HMGB1 and PIC in NRK52E 
cells 
 To confirm that the inflammatory activation of HMGB1 and TLR4 was AngII-induced, 
we pretreated NRK52E cells with losartan (100µM), an AT1 receptor blocker. We determined 
the mRNA expression levels (Figure 2.2A) of HMGB1, TLR4, TNFα and IL-1β and protein 
expression (Figure 2.2B-E) levels of HMGB1, TLR4 and TNFα in these cells. The mRNA and 
protein expression levels of HMGB1, TLR4 and TNFα were elevated in AngII treated cells. 
Losartan pretreatment for 2 hours significantly reduced the mRNA and protein expression of 
HMGB1, TLR4 and TNFα in renal tubular epithelial cells. Additionally, losartan treatment 
significantly attenuated the increase in mRNA expression of IL-1β in these cells. As expected, 
there was no difference in gene or protein expression between Vehicle and Vehicle+Los groups.  
Inhibition of TLR4 by RNAi attenuated AngII-mediated production of proinflammatory 
mediators in NRK52E cells 
AngII-treated cells had significantly increased levels of TLR4 and HMGB1 compared with 
control cells (Figures 2.2 and 2.3). Interestingly pretreatment of cells with TLR4siRNA resulted 
in a significant reduction in mRNA (Figure 2.3A) and protein expression levels (Figure 2.3B-E) 
of HMGB1, TLR4 and TNFα. We also observed that the increased expression levels of IL-1β 
mRNA was attenuated in cells treated with TLR4siRNA. There were no differences between 
Vehicle and Vehicle+TLR4siRNA groups. These results demonstrate that pretreatment of cells 





Figure 2.2: Effect of pretreatment with Losartan before AngII exposure in NRK52E cells. Serum 
starved NRK52E cells were pre-treated with losartan for 2 hours before AngII exposure. (A) 
mRNA expression levels of TLR4, HMGB1, TNFα and IL-1β. (B) Representative western blots. 
Densitometric analysis of western blot results showing protein expression of (C) TLR4, (D) 
HMGB1 and (E) TNFα. All values are presented as mean ± SEM (*p < 0.05 vs. Vehicle, #p < 







Figure 2.3: Inhibitory effects of TLR4siRNA on AngII-mediated inflammation in NRK52E cells. 
Serum starved NRK52E cells were transduced with TLR4siRNA for 4 hours before AngII 
exposure. (A) mRNA expression levels of TLR4, HMGB1, TNFα and IL-1β. (B) Representative 
western blots. Densitometric analysis of western blot results showing protein expression of (C) 
TLR4, (D) HMGB1 and (E) TNFα. All values are presented as mean ± SEM (*p < 0.05 vs. 








AngII-mediated production of proinflammatory mediators was attenuated with anti-
HMGB1 treatment in NRK52E cells 
 To demonstrate effects of HMGB1 in AngII-induced production of proinflammatory 
molecules in renal epithelial cells, NRK52E cells were pretreated with anti-HMGB1 and the 
expression of HMGB1, TLR4 and PIC in these cells was examined. We observed that there was 
no difference between Vehicle and Vehicle+antiHMGB1 treatment groups. As determined 
previously, there was a significant elevation in the expression of HMGB1, TLR4 and PIC in 
AngII-exposed cells (Figure 2.4A-E). This increase in the expression of inflammatory molecules 
was reduced with anti-HMGB1 pretreatment in NRK52E cells. These results indicate that AngII-
induced activation of the inflammatory cascade is mediated by HMGB1-TLR4 interaction in 
kidney epithelial cells.  
 We also measured HMGB1 in the medium to assess the levels of HMGB1 released by the 
cells upon treatment. There was a significant increase in the circulating (media) HMGB1 levels 
in AngII treated cells (Figure 2.4F). Anti-HMGB1 treatment or TLR4 silencing in rat tubular 
epithelial cells inhibited this increase in HMGB1 release. This result indicates that AngII-
induced inflammatory injury promotes the release of HMGB1 into the milieu and by treating the 
cells with anti-HMGB1 or TLR4siRNA, AngII-induced proinflammatory cytokine production 
and subsequent injury can be significantly decreased.  
TLR4 siRNA and anti-HMGB1 treatment decreased the number of TLR4-positive 
NRK52E cells 
 We performed flow cytometry on the NRK52E cells to determine if AngII treatment 
increased the number of TLR4-positive cells and if pretreatment with TLR4 siRNA or anti-
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HMGB1 reduced the number of these cells. We observed that AngII treatment induced a 
significant increase in the number of TLR4-positive NRK52E cells (Figure 2.5). 
 
Figure 2.4: Effects of anti-HMGB1 treatment on AngII-mediated inflammation in NRK52E 
cells. Serum starved NRK52E cells were treated with neutralizing anti-HMGB1 for 4 hours 
before AngII exposure. (A) mRNA expression levels of TLR4, HMGB1, TNFα and IL-1β. A (B) 
representative western blots and densitometric analysis of western blot results showing protein 
expression of (C) TLR4, (D) HMGB1 and (E) TNFα. (F) HMGB1 ELISA performed in cellular 
supernatants obtained after treatment of NRK52E cells to determine the level of HMGB1 release. 






Consistent with our RT-PCR and western blot results, there was a significant reduction in the 
number of cells positive for TLR4 upon pretreatment with TLR4 siRNA or anti-HMGB1. These 
data suggest that the HMGB1 result in the upregulated expression of TLR4 that is attenuated in 
anti-HMGB1 treated cells. 
Gene silencing of TLR4 and anti-HMGB1 treatment attenuated NFκB activation and 
reduced the rate of generation of reactive oxygen species in NRK52E cells 
 The activation of TLR4 was confirmed by measuring the NFκB activity. We measured 
the NFκB p65 DNA binding activity in cells from all treatment groups. Consistent with the 
TLR4 expression results, cells exposed to AngII had significantly higher NFκB activity 
compared with the control cells (Figure 2.6A). The TLR4 siRNA transfected cells had a 
significantly lower NFκB activity levels compared with the AngII treated cells suggesting that 
gene silencing of TLR4 inhibited the increase in AngII-induced NFκB activity seen in renal 
epithelial cells. The cells that were pretreated with anti-HMGB1 also exhibited an attenuated 
NFκB activity.  
 TLR4-induced inflammation is known to elevate the generation of reactive oxygen 
species (ROS). We measured the rate of generation of total ROS and superoxide in NRK52E 
cells from all experimental groups (Figure 2.6B-C). There was no change in the rate of 
generation of ROS between control cells and control cells treated with either of these blockers. 
We observed a significant increase in the rate of production of total ROS and superoxide in cells 
that were exposed to AngII. In contrast, pre-treatment with TLR4 gene-silencer and anti-






Figure 2.5: Effects of TLR4siRNA and anti-HMGB1 treatment on AngII-mediated increase in 






Figure 2.6: Inhibitory effects of TLR4siRNA and anti-HMGB1 treatment on AngII-mediated 
NFκB activation and rate of generation of ROS in NRK52E cells. (A) DNA binding activity of 
NFκB p65 subunit in rat renal tubulo-epithelial cells from each experimental group (n=8), as 
determined by ELISA. Rate of generation of (B) Total ROS and (C) Superoxide in the NRK52E 




 The objective of the present study was to investigate the underlying molecular 
mechanisms by which AngII induced renal injury occurs, and to elucidate the role of HMGB1-
TLR4 signaling in mediating this effect. The salient findings of this study include: 1) AngII 
causes activation of the TLR4 inflammatory cascade in renal tubular epithelial cells and 
subsequent up-regulation of PIC; 2) AngII causes an increase in the expression of HMGB1 in 
NRK52E cells; 3) gene-silencing of TLR4 and blockade of HMGB1 reversed the AngII-induced 
effects, suggesting an important role for the TLR4-HMGB1 signaling pathway in mediating 
AngII mediated renal injury. The results of this study support a novel molecular mechanism that 
AngII-induced, increased secretion of HMGB1 leads to over-activation of TLR4, which then 
regulates NFκB to induce the production of PIC. Our data also suggests that AngII-mediated 
renal injury can be ameliorated by inhibiting HMGB1 and TLR4 separately, indicating that these 
molecules are potential therapeutic targets in inflammatory renal diseases.  
 Inflammation is one of the important hallmarks of hypertension and subsequent renal 
injury. TNFα (34), IL-1β (35) and other circulating PIC (35, 36) have been reported to increase 
in the kidney with the severity of hypertension. However, the mechanisms by which 
hypertension contributes to the progression of renal injury is not clear. In this study, we observed 
that AngII exposure resulted in significant up-regulation of TNFα and IL-1β in NRK52E cells 
after 6hrs. Our results are consistent with those of previous studies which have shown that AngII 
infusion increases the production of PIC in rat kidneys (37-39). Although previous studies have 
investigated the effects of AngII on kidneys, the upstream signaling mechanism are not well 
understood. Therefore, we examined the effect of AngII on TLR4, which is an important 
upstream receptor molecule, which can trigger an immune response and, on HMGB1, which is 
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an important inflammatory molecule and an endogenous ligand of TLR4. Our data show that 
AngII treatment for 6hr caused an increased expression of HMGB1 and TLR4 in the renal 
tubular epithelial cells.  
 Angiotensin is a vaso-constrictive peptide known to regulate the blood pressure 
homeostasis. The activation of the vaso-constrictive arm of the RAS contributes to the 
progression of many inflammatory diseases. Anti-inflammatory effects of angiotensin receptor 
blockers (ARB) have been well studied in clinical cases of hypertension and other cardio-renal 
abnormalities including stroke (40) and sepsis (41). Despite these studies, there have not been 
many reports that have implicated the involvement of TLR4 signaling on the AngII-induced 
renal injury model. Hence, we studied the effect of losartan (an ARB) on the inflammatory 
signaling cascade activated by TLR4. Our results clearly show that blockade of angiotensin 
receptors attenuate the TLR4-mediated inflammation by down-regulating TLR4 and HMGB1 
expression levels. In addition to attenuated TLR4 levels, pretreatment with losartan also reduced 
the expression levels of the downstream PIC, TNFα and IL-1β. 
 Recent research studies have implicated the involvement of toll-like receptors (TLR), 
which are important mediators of innate immune response, in several inflammatory disease 
conditions (29, 42-45). TLR are cell surface glycoprotein receptors that recognize pathogens or 
danger-associated molecular patterns, trigger the innate immune response (46), and are shown to 
induce cytokine production and expression of co-stimulatory molecules via the NFκB signaling 
pathway (47, 48). AngII has been reported to up-regulate TLR4 levels in mouse mesangial cells 
(49), but there are not many studies that investigated a direct role of TLR4 on AngII-induced 
injury of renal tubular epithelial cells. Our data was consistent with the previous findings (29, 
49) that AngII induced an increase in the expression of TLR4 in tubular epithelia. Further, we 
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silenced the gene for TLR4 using highly efficient siRNA to explore the specific effects of TLR4 
in AngII-mediated hypertensive injury. We observed that suppression of TLR4 prevented the 
AngII-induced increase in the generation of TNFα and IL-1β. Our results also showed that 
silencing of TLR4 attenuated the secretion of the inflammatory endogenous ligand, HMGB1, as 
evidenced by reduced gene and protein expression levels of HMGB1 in NRK52E cells.  Since 
NFκB activation is a downstream indicator of TLR4 activity, we measured the activity of NFκB 
in these cells to confirm the role played by TLR4 signaling in kidney cellular injury induced by 
AngII. Our NFκB activity data showed that there was an increased activation of NFκB in 
NRK52E cells on AngII exposure. Interestingly, silencing of TLR4 attenuated the activation of 
NFκB induced by AngII in these cell lines, thus validating our hypothesis that AngII mediated 
injury in renal tubular cells progress through the TLR4 signaling cascade.  
 TLR4 inflammatory signaling is initiated by the binding of a specific ligand of TLR4, 
when the receptor is in its proper functional conformation. HMGB1 is a well-known endogenous 
ligand of TLR4 and HMGB1 has the ability to trigger an inflammatory response (19-21).  
HMGB1-TLR4 interaction results in downstream activation of NFκB, and subsequent 
inflammation via generation of PIC and reactive oxygen species (50). In addition to its ability to 
activate TLR4, HMGB1 by itself is an inflammatory protein (51, 52) released by immune cells 
and necrotic cells (16). Hence, there is interest in investigating the effects of HMGB1 
neutralization in renal diseases. In an AngII-induced in vitro model of kidney injury, we studied 
the modulatory role played by HMGB1. We pretreated the NRK52E cells with neutralizing anti-
HMGB1 before AngII exposure and observed that anti-HMGB1 could attenuate the 
inflammatory effects induced by AngII, thereby indicating a role for HMGB1 in the progression 
of inflammatory injury of the kidneys.  
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 We have clearly shown that TLR4 and HMGB1 are elevated in renal tubular epithelial 
cells upon AngII treatment. Furthermore, we also found that suppression of either of these 
molecules attenuate the AngII-induced inflammation in these cells. There are no studies that 
have established a direct ligand-receptor relationship between AngII and TLR4. Recent studies 
have documented the paracrine effect of HMGB1 in lipotoxicity (53) and urothelial carcinoma 
cell lines (54). HMGB1 treatment is also reported to attribute paracrine activity to human 
fibroblasts (55). So a plausible explanation for this mechanism would be that the injurious effect 
of AngII on cells induces the release of HMGB1 into the extracellular milieu. This HMGB1, via 
paracrine signaling, activates TLR4 on the surface of nearby cells, inducing downstream 
activation of NFκB. Activation of NFκB induces gene transcription of PIC, which leads to 
further increase in ROS production, fostering a positive feedback mechanism, and eventually 
leading to renal injury. An illustration of the pathway that our data support is depicted in Figure 
2.7A-B.  
Limitations 
 In the present study, we have used the NRK52E cell line as our renal tubulo-epithelial 
cell model. Obviously, NRK52E cells may not exhibit the phenotypical characteristics of all 
kinds of cells in the kidney. However, NRK52E cells are widely used as a model to investigate 
AngII-mediated signaling (Yang F et al., 2013, Sanchez-Lopez E et al 2005) and redox 
mechanisms (Rice EK et al, 2003) in the kidneys. Therefore, we believe that the NRK52E cell 
line is an already validated renal tubulo-epithelial cell model for our study. Future studies 
involving other renal epithelial and immune cell types and in vivo experiments using animal 
models of AngII-induced kidney injury are required for further validation of this mechanism.  
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Another important limitation of this study is the involvement of specific AngII receptors in 
AngII-induced inflammatory injury observed in this study. Research studies suggest that the  
 
Figure 2.7A: A schematic showing the mechanisms by which TLR4-HMGB1 signaling 





Figure 2.7B: A schematic showing the novel proposed pathways by which AngII-mediated 





proinflammatory effects of AngII are mediated by AngII type 1 receptor (AT1R). We have 
addressed this by pre-treating the cells with losartan. Our data show that losartan treatment 
caused a down-regulation of PICs in AngII exposed cells. Nevertheless, since there is limited 
evidence of a direct ligand-receptor relationship between AngII and TLR4, we cannot attribute 
the entire AngII-mediated renal injury to HMGB1-TLR4 signaling. Future in vivo studies 
involving an AT1R knock-out model is warranted to elucidate the comprehensive role of TLR4 
signaling in AngII-induced renal injury.  
 HIGHLIGHTS: 
 Ang II induced up-regulation of TLR4 inflammatory cascade in renal tubular cells 
 AngII caused an increase in the expression of HMGB1 in NRK52E cells 
 Increased HMGB1-TLR4 signaling induced subsequent inflammation and PIC production 
 Blockade of TLR4 and HMGB1 attenuated AngII induced inflammation in NRK52E cells 
 HMGB1-TLR4 signaling, a potential pharmacological target in inflammatory renal diseases 
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ROLE OF TLR4 IN LIPOPOLYSACCHARIDE-INDUCED ACUTE KIDNEY INJURY: 
PROTECTION BY BLUEBERRY 
 
• This chapter previously appeared as Anand R. Nair, Gustavo S. Masson, Philip J. 
Ebenezer, Fabio Del Piero, and Joseph Francis. Role of TLR4 in Lipopolysaccharide-
induced Acute Kidney Injury: Protection by Blueberry, Free Rad Biol Med 2014 
Jun;71:16-25. doi: 10.1016/j.freeradbiomed.2014.03.012. It is reprinted by permission of 
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3.1 INTRODUCTION 
 Acute kidney injury (AKI) is a significant cause of morbidity and mortality in patients[1], 
particularly affected by trauma[2]. In addition to the sudden tubular and endothelial cell injury, 
AKI also involves other detrimental effects like apoptosis, intra-luminal obstruction and necrosis 
[3]. Previous studies indicate that the oxidative stress-induced inflammatory cascade causes the 
renal cellular injury in acute renal failure[4]. Hence, there is a need for better strategies to 
attenuate the inflammation that is associated with such conditions, which could also be a 
promising therapy.  
 Inflammation has been implicated in most of the kidney-related disorders, including 
nephropathy [5], hypertension and renal failure. Inflammation triggered by the excessive 
production of proinflammatory cytokines (PIC) has been characterized in hypertension-induced 
renal injury [6]. PIC have been shown to exacerbate ROS generation [7, 8], which can activate 
several intracellular signaling pathways including the one that involves the transcription factor 
NFκB [9, 10]. The NFκB signaling pathway further activates the production of more PIC, which 
in turn increases the ROS generation and therefore gives rise to a vicious cycle. The contribution 
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of Toll-like receptor 4 (TLR4) is of particular interest as it is an important molecule that 
mediates several inflammatory pathways.  
 TLRs are receptors found on the cell surface, which play a key role in the innate immune 
system. TLRs recognize pathogens or foreign molecules and trigger the innate immune response 
and are shown to induce cytokine production and expression of co-stimulatory molecules [11] 
via the NFκB signaling pathway [12, 13]. Another interesting aspect of TLR4 is that it serves as 
the specific ligand for the binding of lipopolysaccharide (LPS), which is the major cell wall 
component of gram-negative bacteria. Incidentally, the TLR4 agonist LPS also causes sepsis and 
acute kidney injury and has been well studied [14]. It has been shown that LPS induced sepsis 
causes hypotension, vascular damage, and reduced tissue perfusion leading to end organ damage 
[15]. Again, the TLR4-specific viral inhibitory peptide VIPER has been shown to potentially 
inhibit TLR4-mediated responses induced by LPS [16]. Taken together, TLR4 is a key molecule 
that could mediate the NFκB inflammatory cascade leading to AKI. 
 Blueberries (BB) are a rich source of antioxidants and known to have very high anti-
inflammatory properties. Studies have previously depicted the beneficial effects of BB in 
lowering mean arterial pressure in hypertensive rats [5], reducing the production of PIC in rat 
glial cells [17] and protecting the kidney from nephropathy [5]. Therefore, we hypothesize that 
BB protect against AKI by modulating TLR4.  To test our hypothesis, we used LPS, a specific 
ligand for TLR4, to induce AKI. In addition, we determined whether BB protect against AKI by 




3.2 MATERIALS AND METHODS 
Ethics Statement 
All experimental procedures were in compliance with all applicable principles set forth in 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Publication 
No.. 85-23, revised 1996). This study was approved by the Institutional Animal Care and Use 
Committee of the Louisiana State University School of Veterinary Medicine (protocol approval 
number 12-007). 
Animals and Experimental design 
Twelve-week old Sprague-Dawley rats from colonies maintained in the Louisiana State 
University School of Veterinary Medicine were used in this study. The original source of breeder 
animals was Harlan (Indianapolis).  All animals were maintained on normal rat chow (ad-
libitum) and water, housed in a temperature- (23±2
o
C), humidity- and light- (12 hour light/dark 
cycle) controlled environment.   
Six groups of eight animals each were used for the experimental protocol: Saline fed 
control (SAL+Cont), BB fed Control (BB+Cont), VIPER-treated Control (VIPER+Cont), saline 
fed-LPS injected (SAL+LPS), BB fed-LPS injected (BB+LPS), VIPER and LPS injected 
(VIPER+LPS). The saline and BB feeding was done for 2 days, once both day (A pilot study was 
conducted to determine the appropriate BB and VIPER doses. Rats were fed with BB for 1 or 2 
days and it was found that 2 day BB feeding was protective). The animals were injected with 
LPS (Sigma Aldrich L3129; 10mg/kg bw i.p) 6 h before performing the acute renal clearance 
experiments. The injections were given at 8 AM in order to minimize the light-dark cycle 
variations. The rats belonging to the VIPER+LPS group were administered with VIPER 
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(0.1mg/kg i.v) 2 h prior to the LPS injection. Rats were euthanized at the end of the acute renal 
clearance experiments and kidneys were obtained for analyses.  
Diets 
The food consumption was measured daily for a week prior to the start of the study. The 
BB powder was obtained from the United States Highbush Blueberry Council (USHBC). The 
BB powder (T10711) is a 50/50 blend of two varieties, Tifblue and Rubel. To prepare the 2% BB 
solution, the BB powder was homogenized in water and filtered. Each rat was supplemented with 
BB equal to 2% of their daily feed intake. This solution was fed to animals by an intra-gastric 
gavage.  
Acute renal clearance experiments 
Rats from all the study groups were subjected to renal clearance experiments at the end of 
the feeding period as described previously [5, 18]. Briefly, each rat was anesthetized with Inactin 
(thiobutabarbital ; 100mg/kg body weight), the right inguinal area was shaved, a small incision 
made, and femoral vessels were carefully isolated. The femoral artery was cannulated with 
heparin-primed (100U/ml) PE-50 polyethylene tubing connected to a pressure transducer 
(PowerLab data acquisition systems; AD Instruments, Colorado Springs, CO) for continuous 
measurement of arterial pressure. The femoral vein was catheterized with heparin-primed PE-50 
tubing for infusion of solutions at 20µl/min. An isotonic saline solution containing 6% albumin 
was infused during surgery. After surgery, the infusion solution was replaced with isotonic saline 
containing 2% bovine serum albumin (BSA), 7.5% inulin (Inutest) and 1.5% PAH, and a 300µl 
bolus of this solution was administered at the start of each clearance experiment. The bladder 
was exposed via a suprapubic incision and catheterized with a PE-160 tube for gravimetric urine 
collection. After a 15-20 minute stabilization period, a 30 minute clearance period was 
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conducted to assess values of renal hemodynamic parameters. An arterial blood sample was 
collected at the end of the 30 minute clearance collection period for measurement of plasma 
inulin and PAH concentrations. Plasma inulin and PAH concentrations were measured 
colorimetrically to determine the glomerular filtration rate (GFR) and renal plasma flow (RPF), 
respectively. 
Electron paramagnetic resonance (EPR) spectroscopy 
Total ROS and superoxide production rates were measured in kidney cortex and medulla 
as previously described [5, 18-20] and in whole blood. The ‘total ROS’ represents all reactive 
oxygen species; however, the major  sources trapped by the spin trap used are superoxide, 
hydrogen peroxide, and hydroxyl radical, with other species as minimal contributors. In addition 
to EPR, there are other reported analytical approaches like the use of chemiluminescent and 
fluorescent probes to measure reactive oxygen and nitrogen species, but all have their merits and 
limitations[21]. All electron paramagnetic resonance (EPR) spectroscopy measurements were 
performed with a benchtop EPR spectrophotometer e-scan R (Noxygen Science Transfer and 
Diagnostics, Elzach, Germany). 1-hydroxy-3 methoxycarbonyl-2,2,5,5-tetramethylpyrollidine 
(CMH) was used to measure total ROS and superoxide in whole blood and kidney tissues.  
Measurement of ROS and superoxide in kidney tissues - Pieces of kidney tissue were 
incubated at 37
0
C with 6.6μl of CMH (200μM) for 30 min for ROS measurement; CMH for 30 
min, then 1.5μl of PEG-SOD (50U/ml) for an additional 30 min for superoxide measurement. 
Aliquots of incubated probe media were then taken in 50μl disposable glass capillary tubes 
(Noxygen Science Transfer and Diagnostics) for determination of total cortical ROS and 
superoxide production, under the EPR settings as described previously[9, 20, 22].   
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Measurement of ROS and superoxide in whole blood – Whole blood (20μl) was added to 
a tube containing 20μl of CMH (400μM), mixed gently for ROS measurement. Superoxide was 
measured by adding 20μl of whole blood to a tube containing 20μl of CMH (400μM) and then 
adding 0.64μl of PEG (50U/ml). In both cases, the samples were taken in 50μl disposable glass 
capillary tubes (Noxygen Science Transfer and Diagnostics) and measured on the EPR 
instrument. 
RNA extraction and Real-Time PCR 
Real-time PCR was used to determine the mRNA expression levels [22-24] of the kidney 
cortical (KC) proinflammatory cytokines (PIC), TLR4 and AKI markers by using specific 
primers. Total RNA was isolated using Trizol Reagent (Invitrogen, CA). The RNA concentration 
was calculated from the absorbance at 260nm and RNA quality was assured by the 260/280 ratio. 
The RNA samples were treated with DNase I (Ambion) to remove any genomic DNA. First 
strand cDNA were synthesized from 2µg RNA with an iScript cDNA synthesis kit (Bio-rad, 
Hercules, CA). Real-Time PCR was performed in 384-well PCR plates using iTaq SYBR Green 
Super mix with ROX (Bio-rad) in triplicate using the ABI Prism 7900 sequence detection system 
(Applied Biosystems, Foster City, CA). The PCR cycling conditions were as follows: 50
o
C for 2 
mins, 95
o
C for 3 min, followed for 45 cycles (15 s at 95
o
C and 1 min at 60
o
C). To confirm the 
specific PCR product, a dissociation step (15 s at 95
o
C, 15 s at 60
o
C and 15 s at 95
o
C) was added 
to check the melting temperature. Gene expression was measured by the ΔΔCT method and was 
normalized to GAPDH or 18s RNA mRNA levels. The data presented are the fold changes of the 
gene of interest relative to that of the control animals. 
60 
 
Western Blotting analysis 
Primary rat TLR4 (SC-30002, Santa Cruz Biotechnology, Inc), KIM-1 (ab-47634, 
Abcam, USA), TNF-α (ab-66579, Abcam, USA) antibodies were used following manufacturer-
recommended dilutions, followed by a horseradish peroxidase-conjugated anti-rabbit IgG 
antibody (SC-2004, Santa Cruz Biotechnology, Inc). Rat primary anti-actin or anti-GAPDH was 
used to confirm the loading and the transfer. We used ImageJ software to analyze the bands.  
Immunofluorescence detection 
Rat tissues were prepared for immunofluorescence as previously described [25, 26]. 
Sequential kidney coronal sections (30µ) were cut with a cryostat (Leica CM 1850; Nussloch, 
Germany) and were collected in tissue culture wells with 0.1M phosphate buffer. Free-floating 
sections were incubated with 2% normal goat serum for 30 min in phosphate buffer (0.1M).  
Mouse anti-TLR4 antibody (1:500 dilution; ab-22048, Abcam, USA) and rabbit anti-KIM-1 
(1:1000 dilution; ab-47634, Abcam, USA) were used for immunofluorescence staining for 24 
hours at 4°C. The primary antibodies were diluted in 0.1M phosphate buffer with 1% normal 
goat serum and 0.1% Triton-X. Slices were washed 5-times with phosphate buffer (0.1M) and 
incubated with goat anti-mouse Alexa 594-conjugated antibody (1:1000 dilution, Invitrogen, 
USA) and goat anti-rabbit Alexa 488-conjugated antibody (1:1000 dilution, Invitrogen, USA) for 
1 h at room temperature. After secondary antibody incubation, slices were washed 3 times with 
phosphate buffer (0.1M) and 6 times with Tris HCl (1M).  Four slices were placed on each slide 
and mounted with a coverslip. 
The histological sections were carefully examined under a fluorescence microscope 
(IX71 Olympus, USA). The images of the kidney sections, with tubules and glomeruli, were 
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digitized at 20x using Olympus DP2-BSW software. Tissue endogenous fluorescence was not 
found at microscope settings which were used to analyze the slide.  
Quantification of NFκB p65 activity 
The NFκB/p65 activity ELISA (Active Motif, USA) kit was used to assess the binding 
activity of free NFκB p65 in nuclear extracts, as described previously [23, 27]. A sandwich 
ELISA method was employed to perform the analysis, according to the manufacturer’s 
instructions.  
3.3 RESULTS 
BB preserves renal hemodynamics in LPS-induced AKI model 
Renal hemodynamic changes are sequelae of AKI and LPS is known to induce a loss of 
function of the kidney, thus contributing to the development of AKI. The kidney function in rats 
from all study groups was assessed to determine the extent of kidney damage. The mean arterial 
pressure (MAP) was not significantly different between control and experimental groups (Fig 3.1 
A).  
However, the hypotensive effect of LPS was evident in the SAL+LPS rats, where the 
MAP decreased when compared to the controls. BB+LPS treatment showed a tendency to 
improve the MAP, but were not statistically significant. The renal clearance experiment showed 
that there was a significant reduction in GFR and RBF and an increase in RVR in SAL+LPS 
animals. In contrast, in the BB+LPS group, there was significant improvement in GFR, RBF and 
a decrease in RVR indicating a renoprotective effect of BB in AKI. Interestingly, we also 
observed an attenuation of renal function parameters in VIPER+LPS animals, indicating a 
specific role of TLR4, at least in part, in the functional decline in the kidneys of LPS-induced 
AKI animals. However, no hemodynamic changes were observed between SAL+Cont, 
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VIPER+Cont (data not shown) and BB+Cont groups (Fig 3.1). These results indicate that BB has 




Figure 3.1: Effect of BB on renal hemodynamic dysfunctions in a LPS-induced AKI model. The 
kidney function of rats from all experimental groups as assessed by renal clearance experiments 




BB inhibits the generation of free radicals in the kidney and whole blood of LPS-induced 
AKI rats 
We measured the rate of generation of free radicals (ROS and superoxide), both tissue 
level (Table 3.1) and circulating (Table 3.2), in animals from all experimental groups. At the 
tissue level, both in kidney cortex and kidney medulla, the production of total ROS and 
superoxide were significantly increased in the SAL+LPS group compared to the rats from 
SAL+Cont, VIPER+Cont (data not shown) and BB+Cont groups. Nevertheless, BB treatment 
attenuated the rate of cortical and medullary free radical production in the BB+LPS animals. 
Animals pretreated with VIPER also, upon LPS administration, had a reduction in the generation 
of these free radicals in the kidney tissue.  
The circulating free radical production was measured in whole blood at the beginning 
(baseline) and at the end of the study (final). Baseline rates of production of total ROS and 
superoxide were not different among the groups. The total ROS and superoxide generation, 
however at the end of the study, was significantly elevated in animals treated with LPS 
(SAL+LPS) compared to their control counterparts. In contrast, animals pre-treated with BB or 
VIPER and injected with LPS (BB+LPS; VIPER+LPS) had a significantly decreased total ROS 
and superoxide in the blood. These results signify that BB exerts an anti-oxidant effect on LPS-
treated AKI model. 
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Table 3.1: Total ROS and superoxide production in the renal cortical and medullary tissue. LPS 
treatment induced an increase in the generation of both total ROS and superoxide in the kidney 
cortex (n=6-8) and medulla (n=6-8). Significantly reduced total ROS and superoxide production 
was noted in the rats pretreated with BB before an LPS insult. VIPER treatment also attenuated 
the total ROS and superoxide production. All values are presented as mean ± SEM (*- p < 0.05 
vs.SAL+Cont, # - p < 0.05 vs. SAL+LPS ,$- p < 0.05  vs. BB+LPS) 
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Table 3.2: Total ROS and superoxide production in the whole blood at baseline and end of the 
study. At baseline (n=6-8), there was no significant difference between the rate of total ROS and 
superoxide production in rats from all experimental groups. However, at the end of the study, the 
LPS treated animals showed a significantly higher rate of total ROS and superoxide generation. 
Pretreatment with BB and VIPER was able to inhibit the increase in the rate of free radical 
production. All values are presented as mean ± SEM (*- p < 0.05 vs. SAL+Cont, # - p < 0.05 vs. 
SAL+LPS ,$- p < 0.05  vs. BB+LPS) 
 
 Control           LPS    
 SAL BB SAL BB VIPER   
Baseline        




1.527±0.123 1.641±0.109 1.600±0.150 1.591±0.121 1.613±0.131   
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BB decreases the expression of TLR4 in the renal cortical tissues of LPS-induced AKI rats 
Since it is well established that LPS is a direct ligand of TLR4, we measured the cortical 
gene and protein expression levels of TLR4 in all experimental groups at the completion of the 
study (Figure 3.2). Both gene and protein expression of TLR4 was elevated in LPS-induced AKI 
rats (Sal+LPS) compared to the saline, VIPER and BB treated controls (SAL+Cont, VIPER+ 
Cont, BB+Cont), indicating that the increased inflammation in the kidney is at least in part due 
to TLR4 activation in these animals. In contrast, pretreatment with BB prevented TLR4 
activation, confirming that renoprotective effect is, at least in part, mediated by TLR4. The TLR4 
expression was however normalized in BB+LPS rats. The decreased protein expression of TLR4 
in VIPER+LPS group also confirms the role of TLR4 in mediating LPS-induced renal injury.  
BB attenuates NF-κB activity and proinflammatory cytokine expression in the kidney of 
LPS-induced AKI animals 
The activation of TLR4 was confirmed by measuring the NFκB activity. We measured the renal 
cortical NFκB p65 DNA binding activity in tissues from saline and BB treated groups (n=7). 
Consistent with the TLR4 expression results, rats from SAL+LPS group had significantly higher 
cortical NFκB activity compared to SAL+Cont and BB+Cont groups (Fig 3.3A). The BB+LPS 
rats had a significantly lower NFκB activity levels compared to the SAL+LPS rats suggesting 
that the BB supplementation prevents the increase in NFκB activity seen in LPS-induced AKI 









Figure 3.2: Effect of BB on renal TLR4 gene and protein expression in a LPS-induced AKI 
model. The (A) mRNA (n=6) and (B) a representative western blot of TLR4 in the renal cortical 
tissues. (C) Bands were analyzed and quantified by densitometry (n=6). The gene and protein 
expression of TLR4 was increased in the LPS treated rats. The pretreatment with BB was able to 
inhibit the increased expression of TLR4 in LPS treated animals and was comparable to VIPER-






Figure 3.3: Effect of BB on the renal inflammatory profile in a LPS induced AKI model. (A) 
DNA binding activity of NFκB p65 subunit in renal cortical tissues of rats from each 
experimental group (n=6), as determined by ELISA. Increased NFκB p65 DNA binding activity 
in LPS treated animals was significantly reduced by BB treatment. The (B) mRNA expression 
(n=6) of TNFα in the renal cortical tissues. (C) A representative western blot showing TNFα 
protein expression. (D) Western blot bands were analyzed and quantified by densitometry. TNFα 
mRNA and protein expression (n=6) were increased in LPS treated group and this was attenuated 
by pretreatment with BB. The TNFα protein expression in the BB + LPS group was comparable 




The expression levels of tumor necrosis factor-alpha (TNF-α) in the renal cortical tissues 
of animals from all experimental groups were measured (Figure 3.3B, C and D) since TNF-α 
predominantly acts via the NFκB dependent pathway. Expression of TNF-α was significantly 
increased in SAL+LPS rats compared to the SAL+Cont, BB+Cont and VIPER+Cont rats. 
However, the levels of TNF-α in BB+LPS and VIPER+LPS rats were comparable to the 
SAL+Cont and BB+Cont rats.  
BB ameliorates the renal damage in LPS-induced AKI rats   
The acute kidney injury caused by the LPS was confirmed by measuring the expression 
levels of acute kidney injury markers. The gene expression levels of KIM-1 (Fig 3.4A), cystatin 
C (Fig 3.4D) and IL-18 (Fig 3.4E), all of which are markers of AKI, and protein expression of 
KIM-1(Fig 3.4B, 3.4C) were determined. Compared to control groups, KIM-1, cystatin-C and 
IL-18 expression was increased in rats of SAL+LPS group but were considerably lower in 
BB+LPS rats. These data suggest that BB supplementation has a protective role in AKI as 
indicated by decreased renal injury markers. The protein expression levels of KIM-1 in animals 
pretreated with VIPER were also assessed in order to investigate the role of TLR4 in the 
progression of renal injury and our data (Fig 3.4B, 3.4C) showed that VIPER treated rats had an 
attenuated KIM-1 protein expression. 
The beneficial effects of BB in the kidneys is, at least in part, TLR4-dependent/ TLR4 and 
KIM-1 cell type localization in the LPS-induced kidney injury 
We performed immunofluorescent double-staining on the kidney to determine if there is 
co-localization of TLR4 and KIM1 in renal tissues. We observed that TLR4 and KIM-1 were 
activated in both glomerular and tubular cells of SAL+LPS animals. We were also able to 





Figure 3.4: Effects of BB on acute renal injury markers in a LPS induced AKI model. The 
expression levels of biological AKI markers were assessed in all experimental groups. The (A) 
mRNA (n=6) and (B) protein expression (n=6-8) of KIM1 was increased in the kidney of LPS 
treated animals. BB and VIPER pretreatment reduced the expression of KIM1 in renal cortical 
tissue. (C) A representative western blot showing KIM1 expression in rats from all study groups. 
The mRNA expression of acute renal injury markers (D) Cystatin-C (n=6) and (E) IL-18(n=6). 




Consistent with our mRNA and western blot results, SAL+LPS animals had markedly 
increased TLR4 and KIM-1 expression in the kidneys, compared to the SAL+Cont and BB+Cont 
groups. The BB+LPS and VIPER+LPS animals, however, had a significantly reduced expression 
of TLR4 and KIM-1 in both glomeruli and tubules, and were comparable to the controls. This 
data indicates an autocrine effect of the TLR4 pathway in activating the inflammatory cascade 
within a cell and inducing cellular injury, thus resulting in the activation of kidney injury 
markers. Treatment with BB could inhibit this TLR4 mediated expression of kidney injury 
marker KIM-1 (Figure 3.5). 
3.4 DISCUSSION  
 The salient finding of this study is that BB protect against renal injury by inhibiting 
TLR4 expression. In addition, BB, by inhibiting TLR4, also improves renal function, thereby 
indicating a direct effect of TLR4 in modulating inflammation in the kidney and renal 
hemodynamics. Most TLR, including TLR4, are known to activate the NFκB inflammatory 
cascade [28,29]. Here, we also show that BB attenuates the NFκB activity, thus confirming the 
renoprotective effect of BB is, at least in part,  mediated by TLR4. We also used VIPER, which 
is a TLR4 specific inhibitory peptide, to substantiate the protective effects of BB.  
 Blueberries are a rich source of antioxidants and are known to have antioxidant and anti-
inflammatory properties. BB are known to contain active antioxidant polyphenols, such as 
anthocyanins, flavanols and phenolic acid. Recent studies have revealed that an anthocyanin-rich 
diet can reduce the risk of myocardial infarction in women [30] and indicated that anthocyanins 





Figure 3.5: Effects of BB on KIM1 and TLR4 expression in renal tissue. Representative 
immunofluorescence images for TLR4 and KIM1 staining in kidney sections from rats from all 
experimental groups. We identified expression of TLR4 and KIM1 in glomeruli and tubules, 
which was dramatically increased on LPS treatment. Interestingly, BB pretreatment, similar to 
VIPER treatment, seems to decrease the staining of TLR4 and KIM1 in the glomeruli and 
tubules. Double-labelled staining revealed a colocalization of TLR4 and KIM1.  
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the beneficial effects of BB in attenuating blood pressure [32] and thus exerting a protective 
effect against hypertension-induced nephropathy in spontaneously hypertensive rats [5]. Even 
though several studies have documented the antioxidant and anti-inflammatory properties of BB, 
precise molecular mechanism by which BB protects against inflammation and inflammation-
associated diseases is not clear. This study was designed to investigate if BB could protect 
against an acute renal injury by modulating TLR4. Here we show for the first time that BB 
treatment attenuates the TLR4 expression in the renal tissue of LPS-induced AKI animals. Since 
we used LPS (a specific ligand for TLR4) to induce AKI and its effect was blocked by BB. This 
result indicate that the renoprotective effects BB are, at least in part, mediated by the inhibition 
of TLR4. 
 AKI is characterized by a sudden loss of function of the kidneys, thus disturbing the body 
fluid homeostasis [33]. It remains a major cause of mortality in Western society and increases the 
risk of end stage renal disease [34, 35]. The most effective way to avoid the development of end 
stage renal disease is to prevent the incidence of AKI or delay its progression. Pharmacological 
therapeutics available for AKI currently have been successful to an extent, but there has been an 
increasing interest in non-pharmacological approaches to treat acute and chronic renal diseases. 
One such non-pharmacological therapeutic method is the use of natural sources of antioxidants, 
such as blueberries.  
 AKI may be a consequence of trauma [2], ischemic injury or a nephrotoxic insult [33]. A 
well-known nephrotoxic agent is LPS (lipopolysaccharide), which is an endotoxin that is found 
on the cell wall of gram-negative bacteria. LPS, a specific ligand for the TLR4 receptor, has been 
used in several animal models to induce septic shock, which is characterized by an inflammatory 
response [36] leading to AKI [37]. Recent studies have shown that the LPS-induced 
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inflammation [38] and renal tubule impairment associated with sepsis [39] are through the 
activation of TLR4. Mice lacking the gene for TLR4, upon ischemia-reperfusion of the kidney, 
had decreased production of proinflammatory cytokines and macrophage infiltration [40]. In this 
study, we used LPS to induce kidney dysfunction in rats. Our findings indicate that the LPS-
treated rats showed a marked decrease in kidney function as evidenced by a reduction in GFR 
and RBF, along with an increase in RVR. These results are consistent with previous findings 
[41-43]. It has been shown that LPS progressively increases RVR in rats even at minimal doses 
[41, 44].  
 In the kidneys, LPS insult has been shown to induce oxidative stress, activating 
generation of ROS [45] and other free radicals [46]. Superoxide anions are known to induce an 
increase in smooth muscle cell contraction by regulating the cytosolic calcium concentration 
[47]. Our EPR data indicate that the rate of generation of total ROS and superoxide in the LPS-
treated animals was increased significantly in the kidney as well as in the whole blood. 
Therefore, this increase in the key mediators of systemic as well as renal oxidative stress can 
cause vasoconstriction of the arterioles [48], thus contributing to the reduction and elevation in 
the RBF and RVR respectively. 
 An increase in RVR has been associated with hypoxia in the kidneys [49]. Under hypoxic 
conditions, the tissue is at a greater risk for injury [50-52], wherein it develops glomerular and 
tubular injury, accompanied by a loss of nephrons. In addition to the hypoxia caused by the 
vascular resistance, LPS has also been shown to induce glomerular and tubulo-interstitial 
damage in the renal tissue [53, 54]. For instance, LPS has been shown to cause ultra-structural 
alterations in the glomerular endothelium [53]. LPS treated mice were shown to have a damaged 
glomerular endothelial surface layer and a 5-fold decrease in the density of the glomerular 
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endothelial fenestrae [53]. This damage to the glomerular endothelium can impede the proper 
filtration of the fluid by the glomerulum. Further, studies have associated KIM-1, a tubular injury 
marker in AKI, with low GFR levels [55]. KIM-1 is a tubular trans-membrane glycoprotein that 
is stimulated after an ischemia-reperfusion or a nephrotoxic insult [56]. Therefore, in the light of 
these reports and our current findings, we can propose that the glomerular and tubulo-interstitial 
injury induced by the LPS is the possible cause of the reduced GFR in these animals. 
Interestingly, the rats from BB+LPS group had significantly improved GFR and RBF, and 
reduced RVR indicating the ability of BB in protecting against oxidative stress, thereby down-
regulating TLR4 levels, hence underlining the role of TLR4 in improved hemodynamics and 
reno-protection.   
 In addition to KIM-1 [57, 58], AKI involves upregulation of other biological injury 
markers like IL-18 [59] and cystatin-C [60]. We measured gene expression levels of these AKI 
markers and protein expression of KIM-1 in the cortical kidney tissues of these rats. Our findings 
indicate that the gene and protein expression of these AKI markers in the kidney in BB+LPS was 
significantly lowered when compared to the SAL+LPS group. Our immunofluorescence data 
indicates a co-localization of TLR4 and KIM-1 in the kidney of LPS-treated rats. As LPS is the 
direct ligand of TLR4, an LPS insult would activate the TLR4 pathway. This activated TLR4 
pathway could possibly have an autocrine effect in the kidney cells, wherein it triggers an 
inflammatory cascade and thereby contributes to cellular injury. This injury caused to the cell 
would elicit the production of KIM-1 and hence result in the increased expression of both TLR4 
and KIM-1 in the same cell. This vicious cycle of increased oxidative stress, TLR4 activation 
and KIM1 will further exacerbate renal injury resulting in the decline in renal function. BB by its 
ability to attenuate oxidative stress and prevent the TLR4 activation, blocks the vicious cycle and 
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its subsequent effect on renal injury, resulting in the restoration of renal function in this AKI 
model. 
 In addition to an attenuated TLR4 expression, BB+LPS exhibited decreased expression of 
PICs. We examined the expression of TNFα in the kidney cortex tissue of animals from all 
experimental groups. We observed that BB+LPS animals expressed a significantly lesser amount 
of TNFα compared to the SAL+LPS rats. This is consistent with the previous findings from our 
lab, which reported that in SHR, a renal function decline involves an association of PICs with 
their transcription factor NFκB [9]. Further, oxidative stress is a key regulator of NFκB activity 
[10] and it produces a positive feedback mechanism related to inflammation and tissue injury. In 
the present study, blueberry was able to decrease oxidative stress induced by an acute LPS insult 
and this antioxidant effect could be responsible for the NFκB inhibition and decreased TLR4 
expression. 
 Having discussed these novel findings of our study, we would also shed light on the 
possible limitations of this study. Firstly, even though we report that the renoprotective effect of 
BB in a LPS-induced AKI model is, at least in part, through TLR4 inhibition, there could be 
other plausible mechanisms that might contribute to the LPS-induced kidney injury and also 
mediate the renoprotective effects of BB. Secondly, at this time we do not know which particular 
component in BB is largely responsible for the renoprotective effect shown in this model. 
  In summary, our results suggest a major role of BB in protecting against LPS-induced 
AKI via a decrease in inflammation and most importantly, this study provides comparative 
evidence for the first time that the mechanism of action of BB is similar to VIPER, via inhibiting 
TLR4 expression. This study also suggests that non-pharmacological antioxidant approaches 
have protective value against renal injury and also divulge a potential target in TLR4 against 
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acute renal injury. Further studies are underway to determine the prospects of natural antioxidant 
sources not just as a preventative, but also as a therapeutic in renal diseases.     
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CHAPTER 4  
A BLUEBERRY-ENRICHED DIET IMPROVES RENAL FUNCTION AND REDUCES 
OXIDATIVE STRESS IN METABOLIC SYNDROME ANIMALS: POTENTIAL 
MECHANISM OF TLR4-MAPK SIGNALING PATHWAY 
 
• This chapter previously appeared as Anand R. Nair, Carrie M. Elks, Jorge Vila, Fabio 
Del Piero, Daniel B. Paulsen and Joseph Francis. A blueberry-enriched diet improves 
renal function and reduces oxidative stress in Metabolic syndrome animals: potential 
mechanism of TLR4-MAPK signaling pathway, PLoS One. 2014 Nov 5;9 (11):e111976. 
doi: 10.1371/journal.pone.0111976. Open access article, no permission required. 
 
4.1 INTRODUCTION 
 Metabolic syndrome (MetS) is characterized by a cluster of health factors that indicate a 
higher risk for renal dysfunction and cardiac diseases. The prevalence of MetS in the United 
States is increasing at an alarming pace, 34% of adults being affected as of 2006 [1]. The 
common factors that contribute to the development of MetS include obesity, diabetes, 
hypertension, and hyperglycemia. MetS develops as a result of an imbalance among dietary 
intake, sedentary lifestyle, glucose metabolism and cardiac control [2]. Interestingly, all of these 
factors also play a crucial role in proper functioning of the kidneys. Oxidative stress triggered by 
the overproduction of reactive oxygen species (ROS) or inefficient antioxidant systems is also 
involved in the development of renal injury [3]. A wide range of pharmacological therapeutics is 
available to combat the factors that lead to MetS, but most have side effects. In this context, the 
need for non-pharmacological approaches to delay the progression of MetS is growing. Many 
fruits, especially berries, have been shown to be excellent sources of antioxidant compounds, 
such as anthocyanins and phenolics [3]. 
 Blueberries (BB), (Vaccinium sp.) have the highest antioxidant capacity among fruits, 
supplemented by anthocyanins, proanthocyanins, flavanols and phenolic acid present in them [4]. 
BB possess known anti-inflammatory and antioxidant properties. We have previously shown that 
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hypertensive rats have increased production of proinflammatory cytokines (PIC) and renin-
angiotensin system (RAS) components [3], and when fed with a BB diet, exhibit reduced 
oxidative stress and improved nephropathy [5]. We recently established that BB protect against 
LPS-induced acute kidney injury by modulating TLR4 expression [6]. Although previous studies 
have reported the beneficial effects of BB, the mechanism by which BB antioxidants protect 
against MetS-induced renal injury has not been explored.  
 Inflammation triggered by excessive PIC production is associated with hypertension-
induced renal injury and cardiac pathology [7]. PIC have been shown to exacerbate ROS 
generation [8, 9], which can activate several intracellular signaling pathways including the NFκB 
pathway [3]. The NFκB signaling pathway leads to the production of more PIC, which in turn 
increases ROS generation and therefore gives rise to a vicious cycle. In MetS, at the cellular 
level, when a cell is under stress from increased fat or sugar concentration, the cell surface 
receptors detect the changes in the external environment, trigger the production of PIC, and 
thereby generate ROS. Hence, the cell surface receptors play an important role in initiating 
inflammation in MetS.  
 Toll-like receptors (TLRs) are pattern recognition receptors that play key roles in the 
innate immune system. TLRs detect pathogens or danger-associated molecular patterns and 
initiate immune cell responses. Toll-like receptor 4 (TLR4), in particular, is shown to induce 
cytokine production and expression of co-stimulatory molecules [10] via the NFκB signaling 
pathway [11, 12]. TLR4 expression is increased in human macrophages in lipid-rich plaques 
[13], indicating TLR4 activation by hyperlipidemia. Further, TLR4, along with TLR2, has been 
shown to be increased in adolescents with MetS [14].  
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 Mitogen-activated protein kinases (MAPKs) are important mediators of inflammation-
induced tissue injury. Interestingly, MAPKs are critical downstream regulators of TLR pathways 
[15, 16]. Although MAPK activation has been studied in inflammation-associated organ 
dysfunction [17, 18] and  has been shown to contribute to insulin resistance [19], the 
involvement of TLR4-mediated MAPK phosphorylation in MetS-induced kidney dysfunction 
has been poorly understood. The objective of this study was to assess the role of TLR4 in MetS-
induced renal damage and to understand the mechanisms by which BB protect against CKD. We 
hypothesized that the renal damage induced by MetS is caused by TLR4 activation and that BB 
protect against the damage by inhibiting TLR4 expression and subsequent downstream MAPK 
phosphorylation.  
4.2 MATERIALS AND METHODS 
Ethics Statement 
All experimental procedures were in compliance with all applicable principles set forth in 
the National Institutes of Health 2011 Guide for the Care and Use of Laboratory Animals. This 
study was approved by the Institutional Animal Care and Use Committee of the Louisiana State 
University School of Veterinary Medicine (protocol approval number 09-008). 
Animals 
Five-week old heterozygous LZR (fa/+) and homozygous OZR (fa/fa) were purchased 
from Harlan and housed in a temperature- (23±2
o
C), humidity- and light- (12 hour light/dark 





Rats were randomly divided into four different groups: LZR Control (LZRCC), LZR 
Blueberry (LZRBB), OZR Control (OZRCC), and OZR Blueberry (OZRBB).  Animals were fed 
control or BB-enriched diets for 15 weeks. All animals were subjected to acute determination of 
glomerular filtration rate (GFR) and renal plasma flow (RPF) at the end of the 15 week feeding 
period. Rats were euthanized and kidneys were excised for analyses. Kidneys were formalin-
fixed, paraffin-embedded, and then sectioned (3μm).  
Diets 
Diets were prepared by Harlan Teklad (Madison, WI) using a reformulated NIH-31 diet 
by adding 20g/kg lyophilized BB or 20g/kg dried corn. The 2% BB diet was prepared by 
homogenizing the berries in water, lyophilizing and adding the preparation to the NIH-31 rodent 
chow. The control diet was prepared with corn instead of BB and the amount of corn in the 
control diet was adjusted to compensate for the added volume of BB, in order to make the two 
diets isocaloric [5]. The food consumption was measured weekly for all four groups.  
Glucose tolerance test 
Blood was obtained by tail nick in conscious, restrained animals. Glucose was measured 
with a handheld glucose meter (One Touch Ultra, USA).  Baseline fasting blood glucose was 
determined after an overnight fast. A glucose bolus (2g/kg of body weight) was then 
administered intraperitoneally, and blood glucose was measured at 15, 30, 45, 60, 90, 120, 150, 
and 180-minute intervals.   
Acute renal clearance experiments 
The OZR animals have been shown to exhibit reduced renal function parameters, namely 
glomerular filtration rate (GFR) and renal blood flow (RBF) even at 12-14 weeks of age. [20, 21] 
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The average GFR of male obese zucker rats at 20 weeks of age was 0.3ml/min/g kidney wt.[21] 
and RBF at 14 weeks was shown to be 6ml/min/g kidney wt. Rats from all the study groups were 
subjected to renal clearance experiments at the end of the feeding period [3, 6]. Briefly, each rat 
was anesthetized with inactin (thiobutabarbital; 100mg/kg body weight), the right inguinal area 
was shaved, a small incision made, and femoral vessels were carefully isolated. The femoral 
artery was cannulated with heparin-primed (100U/ml) PE-50 polyethylene tubing connected to a 
pressure transducer (PowerLab data acquisition systems; AD Instruments, Colorado Springs, 
CO) for continuous measurement of arterial pressure. The femoral vein was catheterized with 
heparin-primed PE-50 tubing for infusion of solutions at 20µl/min. An isotonic saline solution 
containing 6% albumin was infused during surgery. After surgery, the infusion solution was 
replaced with isotonic saline containing 2% bovine serum albumin (BSA), 7.5% inulin (Inutest) 
and 1.5% PAH, and a 300µl bolus of this solution was administered at the start of each clearance 
experiment. The bladder was exposed via a suprapubic incision and catheterized with a PE-200 
tube for gravimetric urine collection. After a 15-20 minute stabilization period, a 30 minute 
clearance period was conducted to assess values of renal hemodynamic parameters. An arterial 
blood sample was collected at the end of the 30 minute clearance collection period for 
measurement of plasma inulin and PAH concentrations as previously described ([5, 6]. Plasma 
inulin and PAH concentrations were measured colorimetrically to determine GFR and RPF, 
respectively. 
Glomerular injury scoring 
A semi-quantitative glomerular scoring method was used, based upon previously 
published methods for glomerular scoring [5]. The method was expanded to include parietal 
metaplasia of Bowman’s capsule, glomerular sclerosis, proteinuria and interstitial nephritis.  
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Measurement of Urinary Albumin levels 
Urine albumin was assessed in animals from all experimental groups using the NephratII 
Albumin Assay Kit (Exocell Inc., Philadelphia, USA) according to manufacturer’s instructions. 
Electron paramagnetic resonance (EPR) spectroscopy 
Total ROS, superoxide, and peroxynitrite production rates were measured in pieces of 
kidney cortex via EPR spectroscopy as previously described [5, 6, 22-25]. The term ‘total ROS’ 
represents all ROS; however, the major  sources trapped by the spin trap used are superoxide, 
hydrogen peroxide, and hydroxyl radical, with other species as minimal contributors.. Briefly, 
tissue pieces were incubated at 37
o
C with 6.6µl of CMH (200µM) for total ROS measurement; 
1.5µl of PEG-SOD (50U/µl) for 30 minutes, then CMH for an additional 30 minutes for 
superoxide measurement; or 30µl of CPH (500µM) for 30 minutes for peroxynitrite 
measurement. Aliquots of incubated probe media were taken in 50µl disposable glass capillary 
tubes (Noxygen Science Transfer and Diagnostics, Elzach, Germany) for determination of total 
ROS, superoxide or peroxynitrite production, under previously established EPR settings [3, 5, 6]. 
RNA extraction and Real-Time PCR 
Real-time PCR was used to determine the expression levels of kidney cortex (KC) PIC 
and TLR4. Total RNA was isolated using Trizol reagent (Invitrogen, CA). The RNA 
concentration was calculated from the absorbance at 260nm and RNA quality was assured by the 
260/280 ratio. The RNA samples were treated with DNase I (Ambion) to remove any genomic 
DNA. First strand cDNA were synthesized from 2µg RNA with iScript cDNA synthesis kit (Bio-
rad, Hercules, CA). Real-time PCR was performed in 384-well PCR plates using iTaq SYBR 
Green Super mix with ROX (Bio-rad) in triplicate using the ABI Prism 7900 sequence detection 





C for 2 mins, 95
o
C for 3 min, followed for 45 cycles (15s at 95
o
C and 1 min at 60
o
C). To 
confirm the specific PCR product, a dissociation step (15s at 95
o
C, 15s at 60
o
C and 15s at 95
o
C) 
was added to check the melting temperature. Gene expression was measured by the ΔΔCT 
method and was normalized to 18s RNA mRNA levels. The data presented are the fold changes 
of the gene of interest relative to that of the control animals. 
Western Blotting analysis 
Primary rat TLR4 (sc-30002), IL-1β (sc-7884), IL-18 (sc-7954), Nrf2 (sc-722) and Keap1 
(sc-33569) antibodies were purchased from Santa Cruz Biotechnology, USA and p38MAPK 
(#9212), p-p38MAPK (#9211), ERK1/2 (#9102) and p-ERK1/2 (#9106) from Cell Signaling, 
USA and used following manufacturer-recommended dilutions, followed by a horseradish 
peroxidase-conjugated anti-rabbit IgG antibody (SC-2004, Santa Cruz Biotechnology, Inc). Rat 
primary anti-GAPDH (sc-25778) or anti-actin (sc-1616) was used to confirm the loading and the 
transfer. We used ImageJ software to analyze the bands.  
Measurement of cortical catalase and superoxide dismutase levels 
Antioxidant levels in renal cortex of animals from all experimental groups were 
quantified. Catalase levels were assessed with a catalase assay kit (Cayman Chemicals, Ann 
Harbor, MI) and superoxide dismutase enzyme levels were determined using a SOD assay kit 
(Dojindo Molecular Technologies, Rockville, Maryland) according to manufacturer’s 
instructions.  
Quantification of NFκB p65 activity 
The NFκB/p65 activity ELISA (Active Motif, USA) kit was used to assess the binding 
activity of free NFκB p65 in nuclear extracts, as described previously [6]. A sandwich ELISA 




Body weight and food intake 
Food consumption and body weight were measured weekly.  Food intake did not differ 
between LZRCC and LZRBB animals or between OZRCC and OZRBB groups. The initial and 
final body weights of the animals in all groups are summarized in Table 1. OZRCC and OZRBB 
had significantly higher body weights compared to the LZR animals that were fed either diet. 
There was no significant difference between the body weights of OZR rats, irrespective of the 
diet. 
BB-enriched diet improves glucose tolerance in MetS animals 
The control OZR had impaired glucose tolerance compared to the LZR. The 
improvements in glucose tolerance over different time-points in BB-fed OZR rats appear in 
Figure 4.1. BB feeding for a period of 15 weeks improved glucose tolerance in OZRBB rats 
compared to the OZRCC group. However, there was no significant difference in the glucose 
sensitivity between LZRCC and LZRBB rats.  
Table 4.1: Average initial and final body weight of rats. The body weight of all rats was 
measured at the start and end of the feeding period. All values are presented as mean ± SEM 
(*- p < 0.05 vs. LZRCC, # - p < 0.05 vs. OZRCC, $- p < 0.05 vs. OZRBB) 
Body Weight LZR OZR 


















Figure 4.1: Effect of BB feeding on glucose sensitivity in MetS animals. The glucose sensitivity 
of rats from all experimental groups as assessed by glucose sensitivity assay (n=7 per group). All 
values are presented as mean ± SEM (*p < 0.05, **p < 0.01) 
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Kidney function is impaired in OZR and blueberry improves renal hemodynamic 
parameters in these animals 
MetS is known to induce a loss of function of the kidney, thus leading to alterations in 
renal hemodynamic parameters. The kidney function in rats from all study groups was assessed 
to determine the extent of kidney damage. The blood pressure trends for each group of rats 
appear in Figure 4.2A. The OZRCC rats had significantly higher mean arterial pressure (MAP) 
compared to the LZR rats. The MAP of OZRBB rats were significantly lower in comparison to 
the OZRCC group by the end of the feeding period. Figures 4.2B-4.2D illustrates the reno-
protective effects of BB-enriched diet in OZR rats fed for 15 weeks. The renal clearance 
experiments showed significant reductions in GFR and RBF, and an increase in renal vascular 
resistance (RVR) in OZRCC animals. In contrast, in the OZRBB rats, there was a significant 
increase in GFR and RBF, and a decrease in RVR, indicating a reno-protective effect of BB. 
There was no significant difference in blood pressure or renal hemodynamic measures between 
LZRCC and LZRBB animals. 
In addition to the kidney function parameters, we also measured the expression of renin-
angiotensin system (RAS) genes in the kidneys of animals from all experimental groups (Figure 
4.3A-4.3D). The OZRCC animals had an elevated expression of ACE and AT1 genes and a 
significantly reduced expression of ACE2 and AT2, compared to the lean controls. Conversely, 
BB enriched diet could significantly attenuate the expression of ACE and AT1, and also 





Figure 4.2: Effect of BB on renal hemodynamic dysfunctions in MetS animals. The kidney 
function of rats from all experimental groups as assessed by renal clearance experiments (n=6-9 
per group) (A) BB supplementation significantly decreased the MAP in obese zucker rats (B) 
MetS animals exhibited a significantly reduced GFR. BB pretreatment improved the GFR in 
MetS animals. (C) MetS animals had a reduced renal blood flow. BB treatment normalized the 
renal blood flow in these animals. (D) The RVR was increased in MetS animals and BB 
prevented this increase in RVR in them. All values are presented as mean ± SEM (*p < 0.05, **p 





Figure 4.3: Effect of BB on renal renin-angiotensin system in MetS animals. The mRNA 
expression of (A) ACE, (B) ACE2, (C) AT1 and (D) AT2 in the renal cortical tissue. The gene 
expression of ACE and AT1 were significantly increased and ACE2 and AT2 were reduced in 
MetS rats. The BB enriched diet was able to attenuate these changes in renin-angiotensin system 




together with the improved renal function, this result of the renin-angiotensin system 
components confirms a protective functional role of BB in the kidneys of MetS animals.  
Kidney structure is altered in OZR and blueberry feeding preserves glomerular 
morphology and structure in these animals 
Masson’s Trichrome-stained kidney sections from rats (n = 6) from all experimental 
groups were examined by a veterinary pathologist who was blinded to the experimental 
conditions. The kidneys of LZRCC and LZRBB exhibited similar appearances histologically. 
Representative photographs of glomeruli for each experimental group appear in Figure 4.4. 
Renal changes in the OZRCC image are evident in glomeruli, tubules and interstitium. There is 
moderate glomerular fibrosis; tubular dilatation and attenuation of lining epithelium with 
intraluminal hyaline casts; tubular atrophy; multifocal to coalescing moderate to severe 
interstitial fibrosis; multifocal interstitial, moderate to severe lymphocytic and plasmacytic 
nephritis. Remarkably, OZRBB animals exhibited less pathological changes with minimal 
interstitial fibrosis (Figure 4.5). When compared to OZRCC, OZRBB exhibited less severe 
glomerular adhesions, cortical and medullary tubular lesions, interstitial nephritis. 
Oxidative stress contributes to the progression of MetS while blueberry diet attenuates free 
radical production rates in MetS animals 
Overproduction of free radicals, mainly ROS and reactive nitrogen species (RNS), is a major 
factor contributing to the progression of MetS. We measured total ROS, superoxide and 
peroxynitrite production rates using EPR spectroscopy in cortical tissues from rats (n=7) in all 
experimental groups (Table 4.2). At the kidney tissue level, the total ROS, superoxide and 
peroxynitrite production rates were significantly higher in OZRCC rats compared to the LZRCC 
and LZRBB rats. However, BB treatment attenuated the rate of cortical and medullary free 
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radical production in the OZRBB animals. Table 4.2 shows the free radical production rates in 
cortical and medullary kidney tissues in rats from all experimental groups.  
 
Figure 4.4: Effect of BB on renal pathology in MetS animals. (A) Representative images of the 
renal pathology of rats from all experimental groups as assessed by Masson’s trichrome staining 
of the kidney sections (n=6). There are no significant renal structural changes visible in LZRCC 
and LZRBB groups. However, renal changes in the OZRCC image are evident in glomeruli, 
tubules and interstitium. There is moderate glomerular fibrosis; tubular dilatation and attenuation 
of lining epithelium with intraluminal hyaline casts; tubular atrophy; multifocal to coalescing 
moderate to severe interstitial fibrosis; multifocal interstitial, moderate to severe lymphocytic 






Figure 4.5: Effect of BB on renal pathology in MetS animals (pathological scoring). (A) Relative 
pathological scoring of glomerular sclerosis, interstitial nephritis and proteinuria as evaluated by 
a veterinary pathologist who was blinded to experimental conditions (n=6). (B) Urinary albumin 
levels (mg/dl) in rats from all experimental groups as determined by the albumin assay kit. 
(
**
p<0.01 to LZRCC, 
***
p<0.001 to LZRCC) 
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Table 4.2: Rate of generation of total ROS, superoxide and peroxynitrite in the kidney cortical 
and medullary tissue. OZRCC animals showed a significantly higher rate of total ROS, 
superoxide and peroxynitrite generation. Pretreatment with BB was able to inhibit the increase in 
the rate of free radical production. All values are presented as mean ± SEM (*- p < 0.05 vs. 











































































































Kidney TLR4 expression is elevated in animals with MetS and blueberry supplementation 
decreases TLR4 expression in the kidney 
TLR4 plays a vital role in activating the immune system in response to inflammation and 
oxidative stress. Kidney cortical TLR4 gene and protein expression was measured in tissues from 
all experimental groups using real time RT-PCR and western blotting technique respectively 
(Figure 4.6). Both gene and protein levels of TLR4 were elevated in OZRCC rats compared to 
the LZR animals, indicating that the increased inflammation in the kidney of MetS animals was, 
at least in part, mediated through TLR4. In contrast, OZRBB rats had an attenuated TLR4 gene 
and protein expression levels when compared to OZRCC rats, and comparable to LZRCC and 
LZRBB animals.  
MetS animals expressed increased phosphorylation of ERK and p38 MAPK and BB 
intervention significantly inhibited the phosphorylation of MAPK 
We examined the expression levels of total and phosphorylated ERK and p38 in the renal 
cortex of animals from all experimental groups. The expression level of p-ERK and p-p38MAPK 
was not significantly different between the LZR animals (Figure 4.7A-4.7C). Consistent with the 
TLR4 expression pattern, the OZRCC exhibited an elevated expression of p-ERK and p-
p38MAPK in the kidneys. In contrast, BB intervention (OZRBB) attenuated the phosphorylation 
of MAPK in these animals. Taken together with the reduced TLR4 expression in MetS rats, these 





Figure 4.6: Effect of BB on renal TLR4 gene and protein expression in MetS animals. The (A) 
mRNA (n=6) and (B) a representative western blot of TLR4 in the renal cortical tissues. (C) 
Bands were analyzed and quantified by densitometry (n=6). The gene and protein expression of 
TLR4 was increased in the MetS rats. The pretreatment with BB was able to inhibit the increased 
expression of TLR4 in MetS animals and was comparable to the LZR controls. All values are 





Figure 4.7: Effect of BB on MAPK signaling in MetS animals. The protein expression of total 
and phosphorylated MAPK (ERK and p38) was determined by western blotting. (A) A 
representative western blot showing ERK and p38MAPK protein expression. Western bands for 
ERK (B) and p38MAPK (C) were analyzed and quantified by densitometry. All values are 
presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001) 
102 
 
NFκB activity and PIC expressions are higher in MetS and blueberry feeding attenuates 
these changes in MetS animals 
The activation of TLR4 was confirmed by measuring the NFκB activity. We measured 
the renal cortical NFκB p65 DNA binding activity in tissues from control and BB treated groups 
(n=6). Consistent with the TLR4 expression results, rats from OZRCC group had significantly 
higher cortical NFκB activity compared to LZRCC and LZRBB groups (Fig 4.8B). The OZRBB 
rats had a significantly lower NFκB activity levels compared to the OZRCC rats suggesting that 
the BB supplementation prevents the increase in NFκB activity seen in MetS animals. 
Gene expression levels of proinflammatory cytokines IL-1β, IL-18, TNFα and protein 
expression levels of IL-1β and IL-18 were measured in all experimental groups (n=6). These 
interleukin levels were significantly reduced in the OZRBB compared to the OZRCC animals 
(Figure 4.8A, 4.8C-4.8E). Again, there was no significant difference in the expression of these 
proteins between the two groups of LZR animals. The difference in the expression of IL-1β and 
IL-18 between the OZR groups is particularly important not only because these are 
proinflammatory molecules, but also as IL-1β and IL-18 are downstream molecules of the TLR4 
pathway. TNFα mRNA expression results were also consistent with the expression of other PIC. 
MetS animals had a reduction in antioxidant defense which was restored by the blueberry 
diet  
We measured the cortical levels of the antioxidant enzymes SOD and catalase in all experimental 
groups (Figure 4.9A-4.9B). SOD catalyzes the conversion of superoxide into oxygen and 
hydrogen peroxide. Catalase breaks down hydrogen peroxide. The SOD and catalase levels were 
depleted in rats belonging to the OZRCC group compared to the LZR groups. A blueberry-
enriched diet significantly increased the SOD and catalase levels in the OZRBB group, 
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indicating a beneficial antioxidant effect of BB in MetS animals. We also determined the protein 
expression levels of redox sensitive transcription factor NF-E2-related factor 2 (Nrf2), which is a  
 
 
Figure 4.8: Effect of BB on the renal inflammatory profile in MetS animals. The (A) mRNA 
expression (n=6) of IL-1β, IL-18 and TGF-β in the renal cortical tissues. (B) DNA binding 
activity of NFκB p65 subunit in renal cortical tissues of rats from each experimental group 
(n=6), as determined by ELISA. Increased NFκB p65 DNA binding activity in MetS animals 
was significantly reduced by BB treatment. (C) A representative western blot showing IL-1β and 
IL-18 protein expression. Western blot bands for IL-1β (D) and IL-18 (E) were analyzed and 





Figure 4.9: Effects of BB on antioxidant enzymes and Nrf2-Keap1 signaling in MetS animals. 
Renal cortical catalase (A) and SOD (B) levels as determined by commercially available kits 
(n=6). (C) A representative western blot showing Nrf2 and Keap 1 protein expression. Western 
bands for Nrf2 (D) and Keap1 (E) were analyzed and quantified by densitometry. All values are 
presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001) 
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 key regulator of antioxidant enzymes and its associated protein Kelch-like ECH associated 
protein 1 (Keap1) in the kidney of animals from all the groups. Nrf2 levels were significantly 
increased and Keap1 concomitantly reduced in the OZRBB group compared to the also 
determined the protein expression levels of redox sensitive transcription factor NF-E2-related 
factor 2 OZRCC (Figure 4.9C-4.9E), indicating an improved anti-oxidant defense system in BB 
fed MetS animals.   
4.4 DISCUSSION  
 The most prominent finding of this investigation is that BB protect against chronic 
kidney disease in the zucker rat model of metabolic syndrome by attenuating TLR4 expression 
and reducing oxidative stress in the kidney. To the best of our knowledge, this study is the first to 
demonstrate that 1) TLR4 signaling and consequent inflammatory cascade, at least in part, 
mediates the renal dysfunction in MetS animals; 2) TLR4-mediated phosphorylation of ERK and 
p38MAPK could be a possible mechanism for the progression of chronic kidney injury in MetS; 
3) BB can protect against chronic kidney injury in MetS animals by inhibiting TLR4 and 
subsequently attenuating MAPK activity; and 4) BB can improve other contributing factors to 
MetS, such as glucose metabolism, by reducing inflammation and improving the redox balance. 
The ability of BB to inhibit TLR4 could be an important advancement towards the identification 
of novel therapeutic strategies.  
 MetS is a progressive health disorder that predisposes an individual to cardio-renal 
dysfunction [26] and its increasing incidence is a matter of concern. The most effective way to 
prevent kidney disease induced by MetS is to prevent the incidence of MetS or to delay its 
progression. However, the mechanism by which MetS exacerbates kidney disease remains 
elusive. In this study, we used zucker rats which are established genetic models of research for 
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MetS. The obese zucker rats (recessive) are characterized by obesity, hyperinsulinemia, 
hypertension and hyperlipidemia. Interestingly, inflammation and oxidative stress have been 
implicated in all these pathological conditions and also in CKD [27]. Therefore, we sought to 
investigate the mechanism that regulates the CKD in these animal models of MetS. We also 
studied if a preventive intervention by BB could attenuate the structural and functional damage 
to the kidney in these MetS animals. Further, we tried to elucidate a molecular mechanism by 
which BB protects against MetS-induced kidney dysfunction. 
 Chronic kidney disease is characterized by a loss of function of the kidneys, which 
disrupts the body fluid homeostasis. Recent studies have demonstrated that kidney disorders are 
impending in MetS [27] and TLR4 blockade protects the kidney in type-2 diabetic mice via 
modulating the inflammatory signaling [28]. In this study, we analyzed renal functional 
parameters in all experimental groups. Our findings indicate that the OZRCC rats had a marked 
decrease in kidney function as evidenced by a reduced GFR and RBF, and increased RVR when 
compared to the lean controls. These findings are consistent with previous studies demonstrating 
that MetS and its components are associated with a reduction in GFR [29, 30]. However, renal 
functional parameters were normalized in the blueberry fed OZR (OZRBB) rats, demonstrating a 
significant increase in the GFR and RBF, and decrease in the RVR compared to their control 
diet-fed obese counterparts.  
 Abnormal activation of the RAS is an important mediator of kidney damage [31] and has 
proinflammatory effects that in turn affect the renal hemodynamic parameters [32]. We 
measured the gene expression levels of RAS components (ACE, ACE2, AT1, AT2) to determine 
their possible role in the renoprotective effect exerted by BB in this study. We found a 
downregulation of the genes (ACE and AT1) in the vasoconstrictor arm of the RAS, and a 
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concomitant upregulated expression of genes belonging to the vasodilatory arm of RAS, namely 
ACE2 and AT2, in the kidney of BB-fed OZR rats, when compared to the control OZR rats.  
These findings suggest that BB-exerted renoprotective effect can be attributed partly to improved 
RAS components in the kidney and indicates yet another pleiotropic effect of BB. 
 Oxidative stress induced generation of reactive oxygen species (ROS) and other free 
radicals has been implicated in MetS [33, 34], pathogenesis of kidney diseases [35-37] and also 
in MetS-induced tubulointerstitial injury [38]. Superoxide anions have been shown to cause 
increased smooth muscle cell contraction by regulating cytosolic calcium concentrations [39]. 
Our EPR data show that the generation of ROS, superoxide and peroxynitrite were increased in 
the medulla and cortical tissue of the kidneys of MetS animals. This increase in the mediators of 
oxidative stress in the kidney tissue can induce vasoconstriction of the arterioles, thus 
contributing to the decreased RBF and elevated RVR in the MetS animals [40]. Further, the 
antioxidant defense mechanism in these OZRCC animals were weak compared to the LZRCC 
and LZRBB rats, as indicated by the SOD and catalase enzyme activity. The BB-enriched diet, 
however, was able to restore the redox balance in the MetS animals. 
 Obesity and hypertension are hallmarks of MetS that have been implicated in kidney 
diseases. In addition to the injury to the kidney tissue [41], proteinuria and microalbuminuria 
have been linked to MetS-associated CKD [27, 42, 43]. Studies have also shown that 
glomerulopathy [41] and injury-induced reduction in the absorption by the tubules result in 
proteinuria [44]. Our histopathological data clearly indicates a marked disruption of the renal 
structure in the OZRCC animals compared to the LZR rats. This structural damage in OZRCC 
animals included glomerular sclerosis, interstitial nephritis, fibrosis and proteinuria. We also 
examined the gene expression of TGF-β, which is an important profibrotic marker [45]. The 
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OZRCC animals had an elevated expression of TGF-β (compared to LZRCC and LZRBB) which 
was significantly reduced in the OZRBB group. Interestingly, previous studies have correlated 
renal TLR4 expression with the inflammatory marker TGF-β in CKD [46]. An increase in TGF-β 
mRNA levels has been implicated in the glomeruli of diabetic rats [47].Further, we also 
measured the albuminuria levels in these animals and our results were consistent with the 
histopathological findings. BB was able to exert a reno-protective effect by attenuating 
nephropathy and albuminuria in OZRBB rats.    
 Inflammation is one of the major contributors to the progression of MetS-induced kidney 
disorders [48, 49]. TLR4 signaling pathways and their expression have been studied in relation to 
inflammation in kidney injury [6, 50]. We examined the gene and protein expression of TLR4 in 
the kidney cortical tissues of animals from all experimental groups. Interestingly, the gene and 
protein expression of TLR4 was significantly increased in the OZRCC rats compared to the 
LZRCC and LZRBB groups. The TLR4 signaling-driven inflammation is, at least in part, a 
possible cause for the progression of glomerular and tubular injury in the MetS animals, thereby 
contributing to renal dysfunction. The MetS animals that were fed on a BB-diet had a reduced 
gene and protein expression of TLR4 in the kidney cortex, thus indicating a protective role of BB 
in the kidney of these animals.  
 Further, to elucidate the downstream mechanism of reno-protection by BB, we examined 
the association of TLR4-mediated MAPK activation in MetS-induced kidney dysfunction. 
Previous findings have established a potential link between ERK1/2 phosphorylation and 
oxidative stress-induced insulin resistance [19], which is a characteristic of MetS. Xi L. et al 
recently showed that selective inhibition of ERK1/2 in rat hepatocytes improved impaired insulin 
signaling [51]. In addition, inhibition of p38MAPK signaling pathways has been shown to 
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prevent diet-induced MetS in rats [52]. Although MAPK activation has been shown in LPS-
induced kidney dysfunction [17, 18, 53], a role for the TLR4-MAPK pathway in MetS-induced 
CKD has never been investigated. Our findings demonstrate phosphorylated-ERK and 
p38MAPK in OZRCC animals compared to the LZRCC and LZRBB. Interestingly, BB-treated 
OZR -had suppressed ERK and p38MAPK activity in the kidneys. This inhibition of MAPK 
activation in OZRBB animals could also be a plausible explanation for the improved glucose 
sensitivity in these animals. Therefore, these results not only designate a key role of TLR4-
MAPK signaling in MetS-associated CKD but also indicate a potential mechanism by which BB 
protects against chronic kidney injury. 
 In addition to attenuated TLR4 and MAPK expression, OZRBB exhibited decreased 
expression of PICs. We examined the expression of gene and protein expression of IL-1β and IL-
18 in the kidney cortex of animals from all experimental groups. The importance of IL-1β and 
IL-18 expression patterns in this study is particularly important, not only because these are 
proinflammatory molecules, but also as these are downstream molecules of the TLR4 pathway. 
We observed that OZRBB animals expressed a significantly lower amount of IL-1β and IL-18 
compared to the OZRCC rats. This is consistent with the previous findings from our lab, which 
reported that in SHR, a renal function decline involves an association of PICs with their 
transcription factor NFκB [3]. Further, oxidative stress is a key regulator of NFκB activity [54] 
and it produces a positive feedback mechanism related to inflammation and tissue injury. In this 
context, we also measured the NFκB activity in all the groups, as NFκB activity is an indicator of 
TLR4 activation. Our data shows that BB attenuates the NFκB activity in MetS rats, thus 
confirming the reno-protective effect of BB is, at least in part, mediated by TLR4.  
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 NFκB and MAPK pathways regulate the expression of many genes involved in 
inflammation and tissue injury [55, 56] and their inhibition has been shown to have tissue 
protective effects. The Nrf2 antioxidant pathway is a key mechanism in the attenuation of kidney 
injury [57] by reno-protective agents [58, 59]. Several mechanisms of Nrf2 activation have been 
reported, including MAPK signaling pathways. In normal physiological conditions, the MAPK 
family maintains the much needed balance between NFκB and Nrf2 activation [60]. In 
pathological conditions though, the pro-oxidative NFκB arm dominates and contributes to the 
increased generation of pro-inflammatory cytokines and ROS, thus weakening the anti-oxidant 
defense system. Nrf2 and Keap1 protein expression were examined in the cytoplasmic extracts. 
Nrf2 regulates the expression of several anti-oxidant enzymes within the cell. Although Keap1 is 
known to regulate the cytoplasmic-nuclear shuttling of Nrf2, it also controls the degradation of 
Nrf2 [61]. A higher expression level of Nrf2, concomitant with a reduced expression level of 
Keap1 in the cytoplasmic fraction indicates increased cyto-protective activity. Therefore, we 
assessed the expression levels of Nrf2 and Keap1 in the cytoplasmic fraction. Our data indicate 
that BB intervention inhibits TLR4 in chronic kidney disease, thereby augmenting the anti-
inflammatory actions of Nrf2 over the pro-inflammatory actions of NFκB. In light of these 
findings, we underline the anti-inflammatory and antioxidant properties of BB, wherein the reno-
protective effect could be due to a suppression of inflammation and subsequent increase in anti-
oxidant mechanism or vice versa. 
 In summary, our results suggest a major role for blueberry in protecting against MetS-
associated CKD via a decrease in inflammation and most importantly, this study provides 
comparative evidence for the mechanism of action of BB, via inhibition of TLR4, and 
consequent attenuation of ERK and p38MAPK phosphorylation. This study also suggests that 
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non-pharmacological antioxidant approaches have protective value against MetS-associated 
CKD and also open up the possibility of a potential target in TLR4 against renal diseases. 
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CHAPTER 5  
SUMMARY AND CONCLUSIONS 
 
5.1 OVERALL SUMMARY OF FINDINGS 
The incidence of renal diseases is on the rise in the United States and statistics show that 
more than 20 million American adults have some kind of kidney diseases (1). If left untreated, 
these acute and chronic kidney disease conditions might progress to End Stage Renal Disease 
(ESRD). End Stage Renal Disease still remains a leading cause of mortality and morbidity in the 
United States (2). An important molecule that is upstream of several inflammatory cascades, 
TLR4, has been associated with the injurious effects of inflammation on the renal structure and 
function (3-5). Although previous studies have proposed a vital role for TLR4 in acute and 
chronic renal diseases, the mechanisms by which TLR4 exerts its inflammatory effect on the 
kidneys are still poorly understood. The overall aim of this dissertation was to elucidate the 
signaling mechanisms by which TLR4 contributes to the development of acute and chronic 
kidney diseases. We further hypothesized that pharmacological and non-pharmacological 
approaches that inhibit the expression of TLR4 would prevent or delay the progression of renal 
diseases. 
In Chapter 2, we determined the molecular mechanism by which AngiotensinII (AngII) 
induces renal injury by modulating TLR4 signaling using an in vitro model of  rat tubulo-
epithelial cell line. AngII treatment in NRK52E cells induced an increase in the expression of 
inflammatory molecules such as TLR4 and HMGB1, along with increased expression of 
proinflammatory cytokines TNFα and IL-1β. We showed that pretreatment with losartan (an 
AT1 receptor blocker) attenuated the AngII-induced expression of TLR4 and inflammatory 
cytokines. TLR4 gene silencing was used to confirm that AngII-induced inflammation was 
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mediated through TLR4 in these cells. TLR4siRNA treatment in these cells significantly 
decreased the expression of proinflammatory cytokines and HMGB1. Further we treated the cells 
with anti-HMGB1 to investigate if the AngII mediated effect was modulated by HMGB1-TLR4 
signaling. Cells pre-treated with anti-HMGB1 before AngII exposure also expressed an 
attenuated inflammatory profile as seen with TLR4-silenced cells. Downstream activation of 
NFκB and rate of generation of ROS were also decreased on gene silencing of TLR4 and/or 
exposure to anti-HMGB1. These findings indicate a key role for TLR4 signaling in AngII-
mediated inflammation in the renal epithelial cells. Our data also reveal that AngII-induced 
effects could be alleviated by HMGB1-TLR4 inhibition, suggesting this pathway as a potential 
therapeutic target for hypertensive renal dysfunctions. 
In Chapter 3, we focused on an in vivo acute kidney injury (AKI) model to elucidate the 
effect of  TLR4 in AKI. We used lipopolysaccharide (LPS) to induce AKI. More importantly, 
LPS is a specific ligand for TLR4. We also used blueberry (a rich source of antioxidants and 
possessing anti-inflammatory properties) supplementation as a potential non-pharmacological 
approach to attenuate the expression of TLR4 and study if blueberry (BB) supplementation could 
prevent or reduce the incidence of LPS-induced AKI. Male Sprague-Dawley rats received a BB 
solution or saline intra-gastric gavage for 2 days. One group of BB and saline gavaged animals 
was injected with LPS (10mg/kg b.w). Another group of rats was injected with VIPER 
(0.1mg/kg i.v), a TLR4 specific inhibitory peptide, 2 hours before LPS administration. 
Compared to LPS-administered rats, the BB pretreated animals exhibited improved glomerular 
filtration rate, elevated renal blood flow, and a reduced renal vascular resistance. In addition, a 
reduction in the rate of production of free radicals, namely total reactive oxygen species (ROS) 
and superoxide, was observed in the BB supplemented LPS group. Gene and protein expression 
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for TLR4, proinflammatory cytokine and acute kidney injury markers were also attenuated in 
animals that were pretreated with BB as measured by real time RT-PCR and western blotting 
respectively. The results in the BB pretreated group were consistent with the VIPER treated rats. 
These results highlight a role for TLR4 in LPS-induced AKI, and suggest that BB, by inhibiting 
TLR4 and its subsequent effect on inflammatory and oxidative stress pathways, is a viable non-
pharmacological option to decrease AKI.  
In Chapter 4, we examined the effect of TLR4 signaling in an animal model of metabolic 
syndrome-associated chronic kidney disease (CKD) and investigated if a blueberry-enriched diet 
could attenuate the progression of CKD in this animal model. We extended our study to further 
investigate the downstream mechanism of TLR4 signaling that contributes to the progression of 
CKD in these animals. We tested the hypothesis that inflammation-induced renal damage is 
triggered by the activation of TLR4, and subsequent modulation of redox-sensitive molecules 
and the mitogen-activated protein kinase (MAPK) pathway. Five-week old lean and obese 
zucker rats (LZR and OZR) were fed a BB-enriched diet or an isocaloric control diet for 15 
weeks. We showed that control OZR exhibited lower glucose tolerance, exacerbated renal 
dysfunction, and increased oxidative stress. Gene and protein expression levels of TLR4 were 
higher and this was accompanied by increased renal pathology with extensive albuminuria and 
deterioration in antioxidant levels in OZR. In addition, OZR had increased phosphorylation of 
ERK and p38MAPK. BB-fed OZR exhibited significant improvements in all these parameters 
compared to OZR. These results suggest that the TLR4-MAPK signaling pathway is a key to the 
renal structural injury and dysfunction in MetS and BB protect against this damage by inhibiting 
TLR4. This is the first study to demonstrate a potential mechanism of TLR4-induced kidney 
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damage in a model of MetS and elucidate a downstream mechanism by which BB exert their 
reno-protective effects. 
5.2 SIGNIFICANCE OF THE RESEARCH AND FUTURE DIRECTIONS 
Despite the recent advances in its treatment, renal diseases still remain a leading cause of 
mortality and morbidity in the United States (2). Oxidative stress (6, 7), inflammation and 
inflammation-associated diseases such as hypertension (8-10), diabetes (11, 12) are major 
contributors to the development of kidney disorders and its progression to end stage renal 
disease. Currently available antioxidative and anti-inflammatory therapies modulate oxidative 
stress and inflammation in the kidney but their efficacy in treating renal diseases is marginal at 
best. The increased rate of incidence of renal diseases in the United States warrants the need for 
new strategies for the treatment of acute and chronic renal diseases.  
Recent evidence indicates an important role for TLR4 in inflammation and inflammatory 
diseases. However, the effect of TLR4 activation on acute and chronic kidney diseases is still 
poorly understood. In addition, the signaling mechanism for the TLR4-associated inflammatory 
effect in renal diseases has not been elucidated. Thus, a better understanding of the causative role 
of TLR4 in the development of renal diseases is important for the identification of novel 
therapeutic targets.  
Our studies have focused on elucidating the mechanisms by which TLR4 modulates the 
inflammatory cascade and thereby contributes to the progression of renal diseases in different 
models of acute and chronic kidney disease. We have shown that targeting TLR4, both 
pharmacologically and non-pharmacologically, is an effective method for attenuating renal 
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